

UNITED STATES OF AMERICA
Congress of the United States

To Dorothy A. Fink, M.D.
Acting Secretary
United States Department of Health and Human Services
200 Independence Avenue, S.W.
Washington, D.C. 20201

Greeting:


Pursuant to lawful authority, YOU ARE HEREBY COMMANDED to appear before the SENATE PERMANENT SUBCOMMITTEE ON INVESTIGATIONS OF THE COMMITTEE ON HOMELAND SECURITY AND GOVERNMENTAL AFFAIRS of the Senate of the United States, on February 18, 2025, at 6 o'clock p.m., in Room 199, Russell Senate Office Building, then and there to testify what you may know relative to the subject matters under consideration by said Subcommittee, and produce all materials as set forth in Schedule A, attached hereto and made a part thereof.

Hereof fail not, as you will answer your default under the pains and penalties in such cases made and provided.

To Subcommittee staff or United States Marshals Service to serve and return.

Personal appearance in Washington, D.C., waived if subpoenaed materials are produced to the Subcommittee on or before the herein appointed date and time.

Given under my hand, by authority vested in me by the Committee, on this 28th day of January, 2025.



Chairman, Senate Permanent Subcommittee on Investigations of the Committee on Homeland Security & Governmental Affairs.



United States Senate
WASHINGTON, DC 20510

January 28, 2025

Dr. Dorothy Fink
Acting Secretary
Department of Health and Human Services
Hubert H. Humphrey Building
200 Independence Avenue, S.W.
Washington, D.C. 20201

Dear Acting Secretary Fink:

For years the Department of Health and Human Services (“HHS”) has ignored my requests for information regarding the origins of COVID-19 and the development and safety of the COVID-19 vaccines. Now, as chairman of the Permanent Subcommittee on Investigations (“PSI” or the “Subcommittee”), I am able to compel records and data that for far too long HHS has refused to release. Accordingly, the enclosed subpoena requires HHS to provide the Subcommittee information on:

1. Previously withheld or heavily redacted communications about the pandemic, including Dr. Anthony Fauci’s emails, including but not limited to the approximately 50 pages of his emails that have been withheld from my office since September 2021;
2. Safety surveillance data on the COVID-19 vaccines including proportional reporting ratios and empirical Bayesian data mining;
3. Unredacted records previously released through Freedom of Information Act requests regarding the government’s awareness of myocarditis and pericarditis cases in post-vaccinated individuals;
4. Data and records relating to COVID-19 vaccine lots associated with higher rates of adverse events;
5. Order forms and receipts showing government researchers purchasing DNA sequences from a biotechnology company; and
6. All communications relating to HHS’s receipt of and response (or lack thereof) to my oversight letters between January 2021 and the present.

The subpoena is issued pursuant to PSI's authority under Senate Resolution 59 (118th Cong.), Rule XXVI of the Standing Rules of the Senate, and Rule 2 of the Rules of Procedure for the Subcommittee. You are required to provide the information detailed in the subpoena by February 18, 2025.

Sincerely,



Ron Johnson
Chairman
Permanent Subcommittee on Investigations

cc: The Honorable Richard Blumenthal
Ranking Member
Permanent Subcommittee on Investigations

Attachments

SCHEDULE A

1. The following documents identified with bates numbers previously produced to Senator Johnson, including any attachments contained or referenced in the documents identified below:¹

JohNIH-00000011
JohNIH-00000012
JohNIH-00000013
JohNIH-00000014
JohNIH-00000015
JohNIH-00000028
JohNIH-00000029
JohNIH-00000030
JohNIH-00000031
JohNIH-00000150
JohNIH-00000151
JohNIH-00000158
JohNIH-00000165
JohNIH-00000166
JohNIH-00000169
JohNIH-00000170
JohNIH-00000173
JohNIH-00000174
JohNIH-00000179
JohNIH-00000180
JohNIH-00000203
JohNIH-00000204
JohNIH-00000206
JohNIH-00000207
JohNIH-00000208
JohNIH-00000225
JohNIH-00000226
JohNIH-00000227
JohNIH-00000228
JohNIH-00000229
JohNIH-00000230
JohNIH-00000231
JohNIH-00000232
JohNIH-00000233

¹ Records identified here with a bates number between JohNIH-00000001 and JohNIH-00004079 are associated with a July 27, 2021 production from HHS; Records identified here with a bates number between JohNIH-00004080 and JohNIH-00004281 are associated with an August 17, 2021 production from HHS.

JohNIH-00000234
JohNIH-00000235
JohNIH-00000236
JohNIH-00000237
JohNIH-00000238
JohNIH-00000239
JohNIH-00000240
JohNIH-00000254
JohNIH-00000292
JohNIH-00000293
JohNIH-00000294
JohNIH-00000422
JohNIH-00000423
JohNIH-00000424
JohNIH-00000425
JohNIH-00000426
JohNIH-00000427
JohNIH-00000428
JohNIH-00000429
JohNIH-00000432
JohNIH-00000433
JohNIH-00000434
JohNIH-00000435
JohNIH-00000436
JohNIH-00000437
JohNIH-00000438
JohNIH-00000450
JohNIH-00000451
JohNIH-00000452
JohNIH-00000453
JohNIH-00000454
JohNIH-00000504
JohNIH-00000505
JohNIH-00000553
JohNIH-00000554
JohNIH-00000555
JohNIH-00000564
JohNIH-00000565
JohNIH-00000722
JohNIH-00000723
JohNIH-00000784
JohNIH-00000785
JohNIH-00000786

JohNIH-00000787
JohNIH-00000789
JohNIH-00000790
JohNIH-00000791
JohNIH-00000811
JohNIH-00000812
JohNIH-00000855
JohNIH-00000856
JohNIH-00000857
JohNIH-00000865
JohNIH-00000866
JohNIH-00000867
JohNIH-00000868
JohNIH-00000869
JohNIH-00000870
JohNIH-00000871
JohNIH-00000872
JohNIH-00000873
JohNIH-00000874
JohNIH-00000875
JohNIH-00000876
JohNIH-00000877
JohNIH-00000891
JohNIH-00000892
JohNIH-00000893
JohNIH-00000894
JohNIH-00000895
JohNIH-00000896
JohNIH-00000904
JohNIH-00000909
JohNIH-00000910
JohNIH-00000954
JohNIH-00000955
JohNIH-00000965
JohNIH-00000966
JohNIH-00001012
JohNIH-00001013
JohNIH-00001018
JohNIH-00001124
JohNIH-00001125
JohNIH-00001128
JohNIH-00001129
JohNIH-00001130

JohNIH-00001131
JohNIH-00001132
JohNIH-00001133
JohNIH-00001134
JohNIH-00001140
JohNIH-00001141
JohNIH-00001142
JohNIH-00001143
JohNIH-00001144
JohNIH-00001145
JohNIH-00001146
JohNIH-00001150
JohNIH-00001151
JohNIH-00001152
JohNIH-00001153
JohNIH-00001163
JohNIH-00001174
JohNIH-00001175
JohNIH-00001176
JohNIH-00001177
JohNIH-00001178
JohNIH-00001179
JohNIH-00001180
JohNIH-00001184
JohNIH-00001185
JohNIH-00001192
JohNIH-00001193
JohNIH-00001194
JohNIH-00001195
JohNIH-00001196
JohNIH-00001197
JohNIH-00001198
JohNIH-00001199
JohNIH-00001210
JohNIH-00001211
JohNIH-00001212
JohNIH-00001230
JohNIH-00001231
JohNIH-00001232
JohNIH-00001233
JohNIH-00001241
JohNIH-00001242
JohNIH-00001243

JohNIH-00001264
JohNIH-00001265
JohNIH-00001266
JohNIH-00001267
JohNIH-00001268
JohNIH-00001269
JohNIH-00001270
JohNIH-00001271
JohNIH-00001272
JohNIH-00001273
JohNIH-00001274
JohNIH-00001279
JohNIH-00001280
JohNIH-00001281
JohNIH-00001284
JohNIH-00001285
JohNIH-00001287
JohNIH-00001290
JohNIH-00001291
JohNIH-00001306
JohNIH-00001307
JohNIH-00001308
JohNIH-00001309
JohNIH-00001311
JohNIH-00001312
JohNIH-00001313
JohNIH-00001374
JohNIH-00001375
JohNIH-00001376
JohNIH-00001377
JohNIH-00001378
JohNIH-00001379
JohNIH-00001380
JohNIH-00001386
JohNIH-00001387
JohNIH-00001388
JohNIH-00001389
JohNIH-00001390
JohNIH-00001391
JohNIH-00001392
JohNIH-00001393
JohNIH-00001394
JohNIH-00001395

JohNIH-00001396
JohNIH-00001397
JohNIH-00001398
JohNIH-00001401
JohNIH-00001429
JohNIH-00001430
JohNIH-00001431
JohNIH-00001441
JohNIH-00001442
JohNIH-00001443
JohNIH-00001450
JohNIH-00001451
JohNIH-00001452
JohNIH-00001453
JohNIH-00001454
JohNIH-00001455
JohNIH-00001456
JohNIH-00001457
JohNIH-00001458
JohNIH-00001459
JohNIH-00001460
JohNIH-00001461
JohNIH-00001481
JohNIH-00001482
JohNIH-00001483
JohNIH-00001484
JohNIH-00001488
JohNIH-00001489
JohNIH-00001490
JohNIH-00001494
JohNIH-00001495
JohNIH-00001496
JohNIH-00001497
JohNIH-00001498
JohNIH-00001499
JohNIH-00001503
JohNIH-00001504
JohNIH-00001505
JohNIH-00001506
JohNIH-00001507
JohNIH-00001508
JohNIH-00001509
JohNIH-00001510

JohNIH-00001511
JohNIH-00001512
JohNIH-00001513
JohNIH-00001519
JohNIH-00001533
JohNIH-00001534
JohNIH-00001535
JohNIH-00001536
JohNIH-00001537
JohNIH-00001538
JohNIH-00001539
JohNIH-00001540
JohNIH-00001541
JohNIH-00001542
JohNIH-00001543
JohNIH-00001570
JohNIH-00001571
JohNIH-00001572
JohNIH-00001573
JohNIH-00001574
JohNIH-00001575
JohNIH-00001576
JohNIH-00001611
JohNIH-00001617
JohNIH-00001631
JohNIH-00001632
JohNIH-00001633
JohNIH-00001634
JohNIH-00001635
JohNIH-00001645
JohNIH-00001646
JohNIH-00001647
JohNIH-00001648
JohNIH-00001649
JohNIH-00001650
JohNIH-00001651
JohNIH-00001652
JohNIH-00001653
JohNIH-00001654
JohNIH-00001693
JohNIH-00001694
JohNIH-00001695
JohNIH-00001705

JohNIH-00001706
JohNIH-00001707
JohNIH-00001714
JohNIH-00001715
JohNIH-00001716
JohNIH-00001717
JohNIH-00001718
JohNIH-00001719
JohNIH-00001720
JohNIH-00001721
JohNIH-00001745
JohNIH-00001746
JohNIH-00001747
JohNIH-00001748
JohNIH-00001752
JohNIH-00001753
JohNIH-00001754
JohNIH-00001758
JohNIH-00001759
JohNIH-00001760
JohNIH-00001761
JohNIH-00001762
JohNIH-00001763
JohNIH-00001767
JohNIH-00001768
JohNIH-00001769
JohNIH-00001770
JohNIH-00001771
JohNIH-00001772
JohNIH-00001773
JohNIH-00001774
JohNIH-00001775
JohNIH-00001776
JohNIH-00001777
JohNIH-00001797
JohNIH-00001798
JohNIH-00001799
JohNIH-00001800
JohNIH-00001801
JohNIH-00001802
JohNIH-00001803
JohNIH-00001804
JohNIH-00001805

JohNIH-00001806
JohNIH-00001807
JohNIH-00001812
JohNIH-00001813
JohNIH-00001814
JohNIH-00001815
JohNIH-00001837
JohNIH-00001838
JohNIH-00001839
JohNIH-00001840
JohNIH-00001858
JohNIH-00001859
JohNIH-00001860
JohNIH-00001862
JohNIH-00001863
JohNIH-00001875
JohNIH-00001876
JohNIH-00001877
JohNIH-00001878
JohNIH-00001881
JohNIH-00001891
JohNIH-00001892
JohNIH-00001895
JohNIH-00001896
JohNIH-00001897
JohNIH-00001898
JohNIH-00001899
JohNIH-00001909
JohNIH-00001910
JohNIH-00001911
JohNIH-00001912
JohNIH-00001913
JohNIH-00001914
JohNIH-00001915
JohNIH-00001916
JohNIH-00001917
JohNIH-00001918
JohNIH-00001939
JohNIH-00001940
JohNIH-00001941
JohNIH-00001942
JohNIH-00001943
JohNIH-00001944

JohNIH-00001945
JohNIH-00001946
JohNIH-00001954
JohNIH-00001955
JohNIH-00001957
JohNIH-00001958
JohNIH-00001959
JohNIH-00001960
JohNIH-00001961
JohNIH-00001962
JohNIH-00001963
JohNIH-00001964
JohNIH-00001965
JohNIH-00001966
JohNIH-00001968
JohNIH-00001969
JohNIH-00001970
JohNIH-00001971
JohNIH-00001972
JohNIH-00001976
JohNIH-00001977
JohNIH-00001978
JohNIH-00001979
JohNIH-00001980
JohNIH-00001981
JohNIH-00001982
JohNIH-00001983
JohNIH-00002014
JohNIH-00002015
JohNIH-00002021
JohNIH-00002022
JohNIH-00002023
JohNIH-00002034
JohNIH-00002037
JohNIH-00002038
JohNIH-00002039
JohNIH-00002040
JohNIH-00002041
JohNIH-00002045
JohNIH-00002046
JohNIH-00002047
JohNIH-00002049
JohNIH-00002050

JohNIH-00002051
JohNIH-00002052
JohNIH-00002053
JohNIH-00002060
JohNIH-00002061
JohNIH-00002062
JohNIH-00002063
JohNIH-00002068
JohNIH-00002069
JohNIH-00002077
JohNIH-00002078
JohNIH-00002079
JohNIH-00002087
JohNIH-00002089
JohNIH-00002090
JohNIH-00002091
JohNIH-00002092
JohNIH-00002093
JohNIH-00002094
JohNIH-00002095
JohNIH-00002096
JohNIH-00002097
JohNIH-00002098
JohNIH-00002099
JohNIH-00002100
JohNIH-00002101
JohNIH-00002102
JohNIH-00002116
JohNIH-00002118
JohNIH-00002119
JohNIH-00002121
JohNIH-00002122
JohNIH-00002123
JohNIH-00002126
JohNIH-00002127
JohNIH-00002150
JohNIH-00002166
JohNIH-00002170
JohNIH-00002171
JohNIH-00002185
JohNIH-00002186
JohNIH-00002195
JohNIH-00002196

JohNIH-00002197
JohNIH-00002198
JohNIH-00002203
JohNIH-00002204
JohNIH-00002205
JohNIH-00002211
JohNIH-00002212
JohNIH-00002213
JohNIH-00002230
JohNIH-00002231
JohNIH-00002232
JohNIH-00002233
JohNIH-00002234
JohNIH-00002235
JohNIH-00002238
JohNIH-00002239
JohNIH-00002240
JohNIH-00002241
JohNIH-00002242
JohNIH-00002243
JohNIH-00002244
JohNIH-00002256
JohNIH-00002257
JohNIH-00002258
JohNIH-00002259
JohNIH-00002260
JohNIH-00002261
JohNIH-00002262
JohNIH-00002263
JohNIH-00002294
JohNIH-00002295
JohNIH-00002296
JohNIH-00002297
JohNIH-00002298
JohNIH-00002304
JohNIH-00002305
JohNIH-00002307
JohNIH-00002308
JohNIH-00002309
JohNIH-00002310
JohNIH-00002311
JohNIH-00002312
JohNIH-00002313

JohNIH-00002314
JohNIH-00002340
JohNIH-00002341
JohNIH-00002343
JohNIH-00002344
JohNIH-00002842
JohNIH-00002843
JohNIH-00002844
JohNIH-00003383
JohNIH-00003407
JohNIH-00003408
JohNIH-00003409
JohNIH-00003410
JohNIH-00003411
JohNIH-00003412
JohNIH-00003413
JohNIH-00003519
JohNIH-00003520
JohNIH-00003521
JohNIH-00003745
JohNIH-00003746
JohNIH-00003747
JohNIH-00003800
JohNIH-00003801
JohNIH-00003933
JohNIH-00003934
JohNIH-00003935
JohNIH-00003936
JohNIH-00003937
JohNIH-00003947
JohNIH-00003948
JohNIH-00003949
JohNIH-00003950
JohNIH-00003951
JohNIH-00003952
JohNIH-00003953
JohNIH-00003954
JohNIH-00003955
JohNIH-00003956
JohNIH-00003957
JohNIH-00003958
JohNIH-00003959
JohNIH-00003960

JohNIH-00003961
JohNIH-00004049
JohNIH-00004050
JohNIH-00004051
JohNIH-00004052
JohNIH-00004053
JohNIH-00004054
JohNIH-00004080
JohNIH-00004081
JohNIH-00004082
JohNIH-00004091
JohNIH-00004092
JohNIH-00004093
JohNIH-00004094
JohNIH-00004095
JohNIH-00004096
JohNIH-00004097
JohNIH-00004098
JohNIH-00004104
JohNIH-00004105
JohNIH-00004106
JohNIH-00004107
JohNIH-00004108
JohNIH-00004109
JohNIH-00004110
JohNIH-00004111
JohNIH-00004112
JohNIH-00004119
JohNIH-00004120
JohNIH-00004121
JohNIH-00004122
JohNIH-00004126
JohNIH-00004127
JohNIH-00004128
JohNIH-00004163
JohNIH-00004164
JohNIH-00004165
JohNIH-00004166
JohNIH-00004167
JohNIH-00004168
JohNIH-00004169
JohNIH-00004179
JohNIH-00004180

JohNIH-00004181
JohNIH-00004182
JohNIH-00004183
JohNIH-00004184
JohNIH-00004185
JohNIH-00004186
JohNIH-00004187
JohNIH-00004193
JohNIH-00004194

2. All records referring or relating to Proportional Reporting Ratios and Empirical Bayesian data mining analyses created and reviewed regarding the COVID-19 vaccines including but not limited to copies of the Proportional Reporting Ratios and Empirical Bayesian data mining analyses on the COVID-19 vaccines and any communications about those data analyses.
3. All records previously requested by Senator Johnson in his November 19, 2024, December 5, 2024, and December 13, 2024 letters (*letters are enclosed in Attachment A*).
4. All records referring or relating to the occurrence of adverse events in certain COVID-19 vaccine lots, including but not limited to, any reviews or data analyses of the rates of adverse events in certain COVID-19 vaccine lots.
5. All records referring or relating to HHS's receipt and discussion of and response to Senator Johnson's oversight letters including but not limited to the letters sent on the dates below to HHS and/or its subcomponents:
 - January 22, 2021
 - March 1, 2021
 - May 19, 2021
 - May 20, 2021
 - May 27, 2021
 - June 11, 2021
 - June 28, 2021
 - July 13, 2021
 - July 30, 2021
 - August 12, 2021
 - August 19, 2021
 - August 22, 2021
 - August 26, 2021
 - September 7, 2021
 - September 15, 2021
 - October 5, 2021
 - October 7, 2021
 - October 14, 2021

- November 18, 2021
- November 18, 2021
- December 29, 2021
- January 13, 2022
- February 10, 2022
- March 1, 2022 (two letters sent on this date)
- March 3, 2022
- March 23, 2022
- May 5, 2022
- June 23, 2022
- June 23, 2022
- July 25, 2022
- August 18, 2022
- September 12, 2022
- January 10, 2023
- March 31, 2023
- April 20, 2023
- April 25, 2023
- August 28, 2023
- September 5, 2023 (two letters sent on this date)
- September 21, 2023
- October 25, 2023
- November 15, 2023
- December 21, 2023
- January 12, 2024
- March 15, 2024
- June 25, 2024
- September 4, 2024
- November 19, 2024
- December 5, 2024
- December 13, 2024
- December 18, 2024

For purposes of this subpoena:

The records subpoenaed include all those that are in the custody, control, or possession, or within the right of custody, control, or possession of the Department of Health and Human Services (“HHS”) or any of its agencies, offices, agents, employees, or representatives.

Records shall be produced in their entirety, without abbreviation, modification, or redaction, including all attachments and materials affixed thereto.

All records should be produced in the same manner as they are kept or maintained in the ordinary course of business, or the records should be organized and labeled to correspond to the categories of the records requested. Each category of records subpoenaed shall be construed independently, and no category shall limit the scope of any other category.

If the subpoena cannot be complied with in full, parties subject to this subpoena shall provide a written explanation of why full compliance is not possible and shall comply to the fullest extent possible. For any claim of privilege for a record, whether in whole or in part, shall be identified in a privilege log submitted in response to this subpoena. The privilege log shall identify the privilege being claimed and an explanation of the basis of said claim of privilege. Any record withheld in its entirety pursuant to a claim of privilege, in addition to the requirements identified above, the aforementioned privilege log shall include: the nature of the record being withheld, including the title and subject matter; the author of the record; the author’s title, occupation, and place of employment; and all names, titles, occupations, and places of employment of any and all recipients of the withheld record. For any record responsive to this subpoena for which HHS no longer maintains custody, control, or possession, HHS shall identify the record, explain the circumstances by which it ceased to maintain custody, control, or possession, and, where applicable, identify the entity which currently maintains custody, control or possession of said record.

Records shall be delivered in accordance with the attached Data Delivery Standards.

All attachments referenced in Schedule A of this subpoena shall be considered as part of Schedule A.

Definitions:

1. The term “Records” includes any written, recorded, or graphic material of any nature, regardless of how recorded or created, and whether original or a copy, including, but not limited to the following: agreements; papers; letters and other correspondence; memoranda; reports; notes, whether handwritten, typed or electronically created; studies; analyses; photographs; diagrams; charts; brochures; tabulations; presentations; working papers; documentation of interviews, including notes, transcripts, and recordings; intra-office communications, including instant messages; electronic mail (e-mail) and attachments; contracts; cables; recordings; notations or logs of any type of communication or meeting, including telephone calls and video conference calls; text messages; bulletins; printed materials; teletype; data processing card or worksheets; electronically created documents; databases; machine readable files; data or documents stored on a computer, server, or other electronic storage device; social network content including posts, direct messages, or comments; diaries; questionnaires and responses; data sheets; summaries; minutes; bills; accounts; estimates; projections; comparisons; messages and similar or related materials. Any non-identical copy of a record, including but not limited to a draft, working copy, or version of the record notated in any way, shall be considered a separate and unique record.
2. The term “Department of Health and Human Services” includes, but is not limited to the Department of Health and Human Services, and any agency, office, subcomponent, partnership, joint venture, group, grantee, contractor, predecessors, successors, or any entity which derives funding, whether in whole or in part, through any funds appropriated to the Department of Health and Human Services.
3. The term “relating to” means, whether in whole or in part, involving, concerning, describing, evidencing, or otherwise connecting.
4. The terms “and” and “or” shall be construed broadly and either conjunctively or disjunctively to bring within the scope of this subpoena any information that might otherwise be construed to be outside its scope. The term “any” means both any and all. The singular includes the plural number, and vice versa. The masculine includes the feminine and neuter genders. The use of a verb in any tense, mood, or voice shall be construed as the use of the verb in all other tenses, moods, or voices, as necessary to bring within the scope of this subpoena any information that might otherwise be construed to be outside its scope.

Attachment A

United States Senate

COMMITTEE ON
HOMELAND SECURITY AND GOVERNMENTAL AFFAIRS
WASHINGTON, DC 20510-6250

DAVID M. WEINBERG, STAFF DIRECTOR
WILLIAM E. HENDERSON III, MINORITY STAFF DIRECTOR
LAURA W. KILBRIDE, CHIEF CLERK

November 19, 2024

The Honorable Xavier Becerra
Secretary
Department of Health and Human Services

The Honorable Robert Califf
Commissioner
Food and Drug Administration

Dr. Mandy Cohen
Director
Centers for Disease Control and Prevention

Dear Secretary Becerra, Commissioner Califf, and Director Cohen:

The lack of transparency from your agencies during the Biden presidency has been appalling. Your agencies' refusal to provide complete and unredacted responses and documents to my numerous oversight letters on the development and safety of the COVID-19 vaccines has hindered Congressional oversight and has jeopardized the public's health.

In addition to hiding relevant information from Congress, your agencies have applied heavy redactions to public documents released under Freedom of Information Act (FOIA) requests. These redactions have made many of these public documents hard to understand and, in countless instances, impossible to read. What is clear from these excessive redactions, however, is a concerted effort to obscure Congress' and the public's understanding of your agencies' detection of and response to COVID-19 vaccine adverse events such as myocarditis and pericarditis. The following three examples from May 2021 highlight only a small fraction of communications and documents on myocarditis and pericarditis your agencies continue to conceal.

I. Heavily Redacted Pfizer Report on Myocarditis and Pericarditis

FOIA documents and public reporting indicate that in early 2021, the Centers for Disease Control and Prevention (CDC) received reports about post-vaccinated cases of myocarditis and pericarditis.¹ By May 22, 2021, heavily redacted documents reveal that then-CDC Director

¹ Zachary Stieber, Timeline: COVID-19 Vaccines and Myocarditis, Epoch Times, Apr. 22, 2024, https://www.theepochtimes.com/health/timeline-covid-19-vaccines-and-myocarditis-5317985?utm_source=ref_share&utm_campaign=twitter&rs=SHRNCMMW; Ed Berkovich and Amy Kelly, FOIA'd CDC Emails Reveal Disturbing Myocarditis Timeline Warranting Investigation: Different Messaging Internally Vs. Publicly About COVID-19 Vaccines and Myocarditis, Daily Clout, Nov. 2, 2023, <https://dailyclout.io/foiad-cdc-emails-reveal-disturbing-myocarditis-timeline-warranting-investigation/>; FOIA production: <https://childrenshealthdefense.org/wp-content/uploads/23-00056-for-2-24-2023-Close.pdf> at 666-668,

Rochelle Walensky received Pfizer data regarding myocarditis cases as well as an attachment of a document with the file name, "APPENDIX 3.7 SAFETY EVALUATION OF MYOCARDITIS AND PERICARDITIS.pdf."² The 14-page attachment is completely redacted except for the cover page which indicates that the document is a "Report Prepared by: BioNTech-Pfizer."³

May 22, 2021: Partial email, then-CDC Director Walensky receives Pfizer report on myocarditis/pericarditis⁴

From: (b)(6)
Sent: Sat, 22 May 2021 16:12:05 -0700
To: Walensky, Rochelle (CDC/OD)
Subject: Fwd: Myocarditis //// This is the right attachment
Attachments: APPENDIX 3.7 SAFETY EVALUATION OF MYOCARDITIS AND PERICARDITIS.pdf

The attachment has the Israeli data included. It has all been sent to your team.

Sent from my iPhone

Begin forwarded message:

From: "Caubel, Patrick" <Patrick.Caubel@pfizer.com>
Date: May 22, 2021 at 4:02:35 PM PDT
To: (b)(6)
Subject: Myocarditis //// This is the right attachment

Larry,

This is the data for MYOCARDITIS (excluding pericarditis). Cut-off date is today.

(b)(4)

Number of valid Adverse Events cases reported to Pfizer as of today is (b)(4) are myocarditis cases).

(b)(4)

Attached our latest monthly aggregate analysis .

Patrick

Month	# cases received
Jan 2021	(b)(4)
Feb 2021	
Mar 2021	

710-713; FOIA production: <https://drive.google.com/file/d/1K6B25XjBdKmjW5yEIEpZ1cvnr6jp3RAY/view> at 301-302.

² FOIA production: <https://drive.google.com/file/d/1K6B25XjBdKmjW5yEIEpZ1cvnr6jp3RAY/view> at 424.

³ *Id.* at 426-440.

⁴ *Id.* at 424. FOIA code (b)(4) is used to protect trade secrets and other confidential business information. FOIA code (b)(6) is used to protect information involving matters of personal privacy. *What information is available under the FOIA?* Dep't of Health & Hum. Servs. <https://www.hhs.gov/foia/faqs/what-information-is-available-under-the-foia/index.html> (last visited Nov. 19, 2024).

Cover of 14-Page heavily redacted April 2021 Pfizer report on Myocarditis and Pericarditis⁵

PF-07302048 (BNT162b2) Summary Monthly Safety Report (SMSR) 5	Reporting Period 01 April 2021 through 29 April 2021
--	---

Pfizer-BioNTech COVID-19 Vaccine

Myocarditis and Pericarditis

Report Prepared by:

BioNTech-Pfizer

The information contained in this document is proprietary and confidential. Any disclosure, reproduction, distribution, or other dissemination of this information outside of BioNTech and Pfizer, its Affiliates, its Licensees, or Regulatory Agencies is strictly prohibited. Except as may be otherwise agreed to in writing, by accepting or reviewing these materials, you agree to hold such information in confidence and not to disclose it to others (except where required by applicable law), nor to use it for unauthorized purposes.

CONFIDENTIAL
Page 1

⁵ FOIA production: <https://drive.google.com/file/d/1K6B25XjBdKmjW5yEIEpZ1cvnr6jp3RAY/view> at 426.

As a result of the redactions contained in this Pfizer report and the CDC's May 22, 2021 email, it is unclear what information then-CDC Director Walensky received regarding cases of myocarditis and pericarditis associated with the Pfizer COVID-19 vaccine.

II. CDC's Draft Alert on Myocarditis Risk

Shortly after receiving Pfizer's data on myocarditis and pericarditis then-CDC Director Walensky and other CDC officials, contemplated whether to issue a warning to the public about the risk of myocarditis among the vaccinated.⁶ In May 2021, CDC officials had drafted a Health Alert Network (HAN) message that would have warned the public about the risk of myocarditis.⁷ According to CDC's website, the HAN is "CDC's primary method of sharing cleared information about urgent public health incidents with public information officers; federal, state, territorial, tribal, and local public health practitioners; clinicians; and public health laboratories."⁸

A partially redacted document shows that on May 23, 2021, then-CDC Director Rochelle Walensky received a draft of the HAN message on myocarditis.⁹ The draft HAN cited in the FOIA document was not produced.¹⁰

⁶ Zachary Stieber, EXCLUSIVE: Email Reveals Why CDC Didn't Issue Alert on COVID Vaccines and Myocarditis, Epoch Times, Jan. 26, 2024, <https://www.theepochtimes.com/article/exclusive-email-reveals-why-cdc-didnt-issue-alert-on-covid-vaccines-and-myocarditis-5571675>.

⁷ *Id.*

⁸ Health Alert Network (HAN), Centers for Disease Control and Prevention, Last Reviewed: Mar. 7, 2022, <https://emergency.cdc.gov/han/>.

⁹ FOIA production: <https://drive.google.com/file/d/1K6B25XjBdKmjW5yEIEpZ1cvnr6jp3RAY/view> at 315.

¹⁰ *Id.* (records released in connection with this FOIA request do not contain a copy of the draft HAN attached to the May 23, 2021 email).

May 23, 2023: Then-CDC Director Walensky receives draft warning on myocarditis¹¹

From: Walensky, Rochelle (CDC/OD)
Sent: Sun, 23 May 2021 19:16:09 +0000
To: Walke, Henry (CDC/DDID/NCEZID/DPEI)
Subject: RE: DRAFT_Myocarditis_Advisory_05232021_1109

Great – sounds good...thank you!
R

From: Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>
Sent: Sunday, May 23, 2021 1:33 PM
To: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Subject: RE: DRAFT_Myocarditis_Advisory_05232021_1109

Perfect, will push it through.

I think Health advisory, (b)(5)
(b)(5)

From: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Sent: Sunday, May 23, 2021 1:17 PM
To: Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>
Subject: RE: DRAFT_Myocarditis_Advisory_05232021_1109

Thank you – Will it be a full HAN –
I’m fine with how this reads...grateful.
R

From: Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>
Sent: Sunday, May 23, 2021 1:12 PM
To: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Subject: DRAFT_Myocarditis_Advisory_05232021_1109


Latest HAN.

In a May 25, 2021 email, a CDC official wrote to a redacted individual—reportedly a Pfizer or Moderna employee—and shared that there are ongoing discussions about the “pros” and “cons” of issuing a HAN and that “people don’t want to appear alarmist[.]”¹²

¹¹ *Id.* FOIA code (b)(5) is used to protect inter-agency or intra-agency communications that are protected by legal privileges. *What information is available under the FOIA?* Dep’t of Health & Hum. Servs. <https://www.hhs.gov/foia/faqs/what-information-is-available-under-the-foia/index.html> (last visited Nov. 19, 2024).

¹² Zachary Stieber, EXCLUSIVE: Email Reveals Why CDC Didn’t Issue Alert on COVID Vaccines and Myocarditis, Epoch Times, Jan. 26, 2024, <https://www.theepochtimes.com/article/exclusive-email-reveals-why-cdc-didnt-issue-alert-on-covid-vaccines-and-myocarditis-5571675>. FOIA production included in article at 824.

*May 25, 2021: CDC official tells Pfizer or Moderna employee about HAN discussions*¹³



CDC never issued the HAN alert and, according to public reports, that decision may have been influenced by the Food and Drug Administration (FDA).¹⁴ Instead, on May 28, 2021, CDC published “clinical considerations” on its website regarding myocarditis, stating “increased cases of myocarditis and pericarditis have been reported in the United States after mRNA COVID-19 vaccination (Pfizer-BioNTech and Moderna),” but CDC still “continues to recommend COVID-19 vaccination for everyone 12 years of age and older.”¹⁵

Starting in January 2024, following public reporting on the CDC’s draft HAN alert, my office requested CDC provide all versions of the draft alert, all communications regarding the decision to not issue the HAN and instead publish the clinical consideration, and briefings with the CDC officials involved in the drafting of the HAN. To date, CDC has refused to cooperate with any of these requests.

¹³ *Id.*


¹⁴ Zachary Stieber, FDA Influenced Decision Not to Send Alert on Post vaccination Heart Inflammation: Emails, Epoch Times, Jan. 21, 2024, https://www.theepochtimes.com/health/fda-influenced-decision-not-to-send-alert-on-postvaccination-heart-inflammation-emails-5570033?utm_medium=social&utm_source=twitter&utm_campaign=digitalsub.

¹⁵ *Id.*; Clinical Considerations: Myocarditis and Pericarditis after Receipt of mRNA COVID-19 Vaccines Among Adolescents and Young Adults, Centers for Disease Control and Prevention, May 28, 2021, archived: <https://archive.is/AnF6y#selection-507.0-507.128>. Other FOIA documents indicate that the clinical considerations on myocarditis were posted on May 27, 2021 and then were “pulled down” after ten minutes. Email from Abbigail Tumpsey, Centers for Disease Control and Prevention, to Rochelle Walensky, Dir., Centers for Disease Control and Prevention, May 27, 2021 (on file with Subcomm.).

III. The White House's Talking Points to Rochelle Walensky, Anthony Fauci, and Francis Collins

In late May 2021, as CDC officials reviewed Pfizer data on post-vaccinated cases of myocarditis and pericarditis and as CDC and FDA officials hesitated to issue a public alert about these risks, the Biden White House sent the U.S.'s top public health officials 17 pages of apparent talking points for "tough QA" on COVID.¹⁶ On May 25, 2021, Benjamin Wakana, the White House's Deputy Director for Strategic Communications and Engagement, emailed then-CDC Director Walensky, then-National Institute of Allergy and Infectious Diseases Director Anthony Fauci, and then-National Institutes of Health Director Francis Collins, among others, a document writing, "attached please find the latest tough QA. New topics include:"¹⁷ The "new topics" listed in the email as well as the 17-page attachment are completely redacted.

*May 25, 2021 email from White House to Walensky, Fauci, Collins
with completely redacted 17-page attachment¹⁸*



¹⁶ Ed Berkovich and Amy Kelly, FOIA'd CDC Emails Reveal Disturbing Myocarditis Timeline Warranting Investigation: Different Messaging Internally Vs. Publicly About COVID-19 Vaccines and Myocarditis, Daily Clout, Nov. 2, 2023, <https://dailyclout.io/foiad-cdc-emails-reveal-disturbing-myocarditis-timeline-warranting-investigation/>; FOIA production: https://drive.google.com/file/d/1wgr-jdUTvvc8MgPnngjhcYlX1uC3L_tJ/view at 28-45.

¹⁷ FOIA production: https://drive.google.com/file/d/1wgr-jdUTvvc8MgPnngjhcYlX1uC3L_tJ/view at 28.

¹⁸ *Id.*

The redactions in this email and the attachment make it impossible to know what “tough QA” the Biden White House wanted Walensky, Fauci, and Collins to have on hand. Ultimately, despite your agencies’ awareness of the risks associated with the COVID-19 vaccines, the main talking point from these and other public health officials was uniform and entirely deceptive: the vaccines are safe and effective.

####

For the last several years, I have sent over 60 public letters to federal agencies on COVID-19 regarding the virus’ origins, early treatment, and the development and safety of the vaccines. While your agencies have largely ignored or failed to fully cooperate with my oversight efforts, I can assure you that your obstruction will soon come to an end. In the next Congress, when I become chairman of the Permanent Subcommittee on Investigations, any attempt by your agencies to withhold documents will be met with a subpoena.

Until then, my oversight work must continue and I, once again, call on you to provide full and complete responses to the following requests:

1. An unredacted version of Enclosure 1.
2. All versions of the draft 2021 HAN on myocarditis and communications referring or relating to the drafting of the HAN, the drafting of the clinical considerations on myocarditis, the decision to not release the HAN, and an unredacted version of Enclosure 2.
3. An unredacted version of Enclosure 3.

I also call on your agencies to immediately preserve all records¹⁹ referring or relating to the development, safety, and efficacy of the COVID-19 vaccines. Please provide the requested information no later than December 3, 2024. Thank you for your attention.

Sincerely,



Ron Johnson
Ranking Member
Permanent Subcommittee on Investigations

Enclosures

¹⁹ “Records” include any written, recorded, or graphic material of any kind, including letters, memoranda, reports, notes, electronic data (emails, email attachments, and any other electronically-created or stored information), calendar entries, inter-office communications, meeting minutes, phone/voice mail or recordings/records of verbal communications, and drafts (whether or not they resulted in final documents).

November 19, 2024
Page 9

cc: The Honorable Richard Blumenthal
Chairman
Permanent Subcommittee on Investigations

The Honorable Christi Grimm
Inspector General
Department of Health and Human Services

Enclosure 1

From: (b)(6)
Sent: Sat, 22 May 2021 16:12:05 -0700
To: Walensky, Rochelle (CDC/OD)
Subject: Fwd: Myocarditis //// This is the right attachment
Attachments: APPENDIX 3.7 SAFETY EVALUATION OF MYOCARDITIS AND PERICARDITIS.pdf

The attachment has the Israeli data included. It has all been sent to your team.

Sent from my iPhone

Begin forwarded message:

From: "Caubel, Patrick" <Patrick.Caubel@pfizer.com>
Date: May 22, 2021 at 4:02:35 PM PDT
To: (b)(6)
Subject: Myocarditis //// This is the right attachment

Larry,

This is the data for MYOCARDITIS (excluding pericarditis). Cut-off date is today.

(b)(4)

Number of valid Adverse Events cases reported to Pfizer as of today is (b)(4) are myocarditis cases).

(b)(4)

Attached our latest monthly aggregate analysis .

Patrick

Month	# cases received
Jan 2021	(b)(4)
Feb 2021	(b)(4)
Mar 2021	(b)(4)

Apr 2021	(b)(4)
May 2021	

Country	# cases
Austria	(b)(4)
Belgium	
Canada	
Czech Republic	
Denmark	
Finland	
France	
Germany	
Greece	
Ireland	
Israel	
Italy	
Japan	
Poland	
Portugal	
Serbia	
Spain	
Sweden	
Switzerland	
UK	
US	

Pfizer-BioNTech COVID-19 Vaccine

Myocarditis and Pericarditis

Report Prepared by:

BioNTech-Pfizer

The information contained in this document is proprietary and confidential. Any disclosure, reproduction, distribution, or other dissemination of this information outside of BioNTech and Pfizer, its Affiliates, its Licensees, or Regulatory Agencies is strictly prohibited. Except as may be otherwise agreed to in writing, by accepting or reviewing these materials, you agree to hold such information in confidence and not to disclose it to others (except where required by applicable law), nor to use it for unauthorized purposes.

Enclosure 2

From: Walensky, Rochelle (CDC/OD)
Sent: Sun, 23 May 2021 19:16:09 +0000
To: Walke, Henry (CDC/DDID/NCEZID/DPEI)
Subject: RE: DRAFT_Myocarditis_Advisory_05232021_1109

Great – sounds good...thank you!

R

From: Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>
Sent: Sunday, May 23, 2021 1:33 PM
To: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Subject: RE: DRAFT_Myocarditis_Advisory_05232021_1109

Perfect, will push it through.

I think Health advisory, (b)(5)

(b)(5)

From: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Sent: Sunday, May 23, 2021 1:17 PM
To: Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>
Subject: RE: DRAFT_Myocarditis_Advisory_05232021_1109

Thank you – Will it be a full HAN –
I'm fine with how this reads...grateful.

R

From: Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>
Sent: Sunday, May 23, 2021 1:12 PM
To: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Subject: DRAFT_Myocarditis_Advisory_05232021_1109

Latest HAN.

From: Walke, Henry (CDC/DDID/NCEZID/DPEI)
Sent: Sun, 23 May 2021 17:12:18 +0000
To: Walensky, Rochelle (CDC/OD)
Subject: DRAFT_Myocarditis_Advisory_05232021_1109
Attachments: DRAFT_Myocarditis_Advisory_05232021_1109.docx

Latest HAN.

From: (b)(4) (b)(4) (x)
Sent: Tue, 25 May 2021 15:03:08 +0000
To: Oliver, Sara Elizabeth (CDC/DDID/NCIRD/DVD)
Subject: Re: Publication - Myocarditis

Thanks, Sara. That is very helpful.

(b)(4)

From: Oliver, Sara Elizabeth (CDC/DDID/NCIRD/DVD) <yxo4@cdc.gov>
Sent: Tuesday, May 25, 2021 10:29 AM
To: (b)(4) (b)(4) (x) (b)(4)
Subject: RE: Publication - Myocarditis

EXTERNAL

I haven't heard plans for an MMWR yet. There's just not enough data yet so an MMWR wouldn't make sense at this point. I would anticipate as we have additional data and more formal analyses, there may be an MMWR, but not right now.

The pros and cons of an official HAN are what the main discussions are right now. I think it's likely to be a HAN since that is CDC's primary method of communications to clinicians and public health departments, but people don't want to appear alarmist either.

I am not trying to be vague on purpose- I really don't know. If I had to guess, I would think it's likely to be a HAN, but can't say for sure yet. I anticipate there will be firm decisions within the next 24 hours so I'll let you know.

Thanks-
Sara

From: (b)(4) (b)(4) (x) (b)(4)
Sent: Tuesday, May 25, 2021 10:24 AM
To: Oliver, Sara Elizabeth (CDC/DDID/NCIRD/DVD) <yxo4@cdc.gov>
Subject: Re: Publication - Myocarditis

Hi Sara,

Thanks for your note. Can I just ask what are the possible options where this might be published?

(b)(4)

From: Oliver, Sara Elizabeth (CDC/DDID/NCIRD/DVD) <yxo4@cdc.gov>
Sent: Tuesday, May 25, 2021 10:20 AM

To: (b)(4) (b)(4) (x) (b)(4)

Subject: RE: Publication - Myocarditis

EXTERNAL

(b)(4)

Apologies that there hasn't been more solid communication on this. Unfortunately, I still don't have a firm update to share. Things have been changing rapidly here. As we know more, I will share.

Thanks-
Sara

From: (b)(4) (b)(4) (x) (b)(4)

Sent: Tuesday, May 25, 2021 9:45 AM

To: Oliver, Sara Elizabeth (CDC/DDID/NCIRD/DVD) <yxo4@cdc.gov>

Subject: Publication - Myocarditis

Hi Sara,

I am just checking in to see if you have decided where you will publish your statement on myocarditis. Will it be the MMWR or somewhere else please? And if you have any update on timing, that would be a big help.

We hope to send CDC the report that we are submitting to PRAC sometime this week.

Many thanks.

(b)(4)

 Please consider the environment before printing this email

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.

From: Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)
Sent: Wed, 26 May 2021 17:49:23 +0000
To: Walensky, Rochelle (CDC/OD); Schuchat, Anne MD (CDC/OD)
Cc: Goldstein, Robert (CDC/OD/OADPS); Berger, Sherri (CDC/OCOO/OD); McDonald, Jason (CDC/OD/OADC)
Subject: Draft HAN - still in clearance
Attachments: DRAFT Brief Myocarditis HAN 5.25.2021 to JIC - clean.docx

Draft attached. This is still in clearance.

Sharing as preview.

Enclosure 3

From: Wakana, Benjamin L. EOP/WHO
Sent: Tue, 25 May 2021 03:21:11 +0000
To: Walensky, Rochelle (CDC/OD); Fauci, Anthony (NIH/NIAID) [E]; Slavitt, Andrew M. EOP/WHO; Collins, Francis (NIH/OD) [E]; Murthy, Vivek (HHS/OASH); Smith, Marcella N. EOP/OSTP
Cc: Rowe, Courtney M. EOP/WHO; Berner, Kate EOP/WHO; Munoz, Kevin EOP/WHO; Sams, Ian (HHS/ASPA); Billet, Courtney (NIH/NIAID) [E]; Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD); Hall, Bill (HHS/ASPA); Burklow, John (NIH/OD) [E]; Myles, Renate (NIH/OD) [E]; Lesko, Max (HHS/OASH); Cheema, Subhan N. EOP/WHO; Saez, Mariel S. EOP/WHO; Webb, Cameron C. EOP/WHO; Beckman, Adam (HHS/OASH); Sanchez-Velasco, Marissa EOP/WHO; Beckman, Adam (HHS/OASH); McDonald, Jason (CDC/OD/OADC); Allen, Kirsten (HHS/ASPA); Perry, Sherice (OS/IEA)
Subject: RE: COVID Tough QA
Attachments: Tough QA 5.24.21 11PM.docx

Hi, attached please find the latest tough QA. New topics include:

(b)(5)

Hope this helps,
Ben

+++
Ben Wakana
Deputy Director for Strategic Communications and Engagement
White House COVID Response Team

(b)(6)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

United States Senate

COMMITTEE ON
HOMELAND SECURITY AND GOVERNMENTAL AFFAIRS
WASHINGTON, DC 20510-6250

DAVID M. WEINBERG, STAFF DIRECTOR
WILLIAM E. HENDERSON III, MINORITY STAFF DIRECTOR
LAURA W. KILBRIDE, CHIEF CLERK

December 5, 2024

The Honorable Xavier Becerra
Secretary
Department of Health and Human Services

The Honorable Robert Califf
Commissioner
Food and Drug Administration

Dr. Mandy Cohen
Director
Centers for Disease Control and Prevention

Dear Secretary Becerra, Commissioner Califf, and Director Cohen:

You have, once again, failed to respond to my oversight requests for documents and information relating to COVID-19 vaccine adverse events. Most recently, on November 19, 2024, I wrote to you requesting unredacted records, previously released through Freedom of Information Act (FOIA) requests, regarding your agencies' detection of and response to myocarditis and pericarditis in post-vaccinated individuals.¹ The response deadline for that letter was December 3, 2024 and, to date, my office has not received any of the requested information. It appears that even in the waning days of the Biden administration, your agencies will remain defiant in providing the public with complete information about the COVID-19 vaccines.

Nevertheless, as I made clear in my November 19 letter, my oversight work must continue. If it becomes necessary to subpoena these and other requested records in the next Congress when I become chairman of the Permanent Subcommittee on Investigations, I will do so.

As a follow-up to my November 19 letter requesting unredacted FOIA records relating to COVID-19 vaccine adverse events, I write today to highlight another example of your agencies' response to concerning reports of myocarditis and pericarditis in post-vaccinated individuals. The timeline below details how, in early 2021, officials at the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) were made aware of "a large number of reports" based on Israeli health data that showed "myocarditis, particularly in young people, following the administration of the Pfizer vaccine."²


¹ Letter from Ron Johnson, Ranking Member, Permanent Subcomm. on Investigations, to Xavier Becerra, Secretary, Dep't of Health and Human Services, et. al, Nov. 19, 2024, <https://www.ronjohnson.senate.gov/services/files/00AAFB3D-72EE-475F-94D5-66708B4AA86D>.

² FOIA production: <https://childrenshealthdefense.org/wp-content/uploads/23-00056-for-2-24-2023-Close.pdf> at 712.

February 28, 2021

CDC, and eventually FDA officials, were notified about an apparent request from an Israeli Ministry of Health official to obtain a CDC and FDA point of contact to discuss reports of myocarditis in young people after receiving the Pfizer COVID-19 vaccine.³

Snapshot of Feb. 28, 2021 email⁴




³ FOIA production: <https://childrenshealthdefense.org/wp-content/uploads/23-00056-for-2-24-2023-Close.pdf> at 710-713; Ed Berkovich and Amy Kelly, FOIA'd CDC Emails Reveal Disturbing Myocarditis Timeline Warranting Investigation: Different Messaging Internally Vs. Publicly About COVID-19 Vaccines and Myocarditis, Daily Clout, Nov. 2, 2023, <https://dailyclout.io/foiad-cdc-emails-reveal-disturbing-myocarditis-timeline-warranting-investigation/>.

⁴ *Id.* at 712-713; FOIA code (b)(6) is used to protect information involving matters of personal privacy. *What information is available under the FOIA?* Dep't of Health & Hum. Servs., <https://www.hhs.gov/foia/faqs/what-information-is-available-under-the-foia/index.html> (last visited Nov. 19, 2024).

March 3, 2021

CDC was notified once again about the Israeli Ministry of Health's request to discuss reports of "a large number of myocarditis and pericarditis cases in young individuals soon after Pfizer COVID-19 vaccination."⁵

Snapshot of March 3, 2021 request from Israeli Ministry of Health to CDC to discuss adverse events associated with Pfizer COVID-19 vaccine⁶



March 4, 2021

The Israeli Ministry of Health's request to speak with a CDC expert about cases of myocarditis and pericarditis in post-vaccinated individuals was eventually forwarded to CDC's vaccine safety team lead in the COVID-19 Vaccine Task Force, Dr. Tom Shimabukuro.⁷ However, due to heavy redactions in the FOIA documents, it is unclear what Dr. Shimabukuro communicated to his colleagues regarding the ministry's "Priority HIGH" request.

⁵ FOIA production: <https://childrenshealthdefense.org/wp-content/uploads/23-00056-for-2-24-2023-Close.pdf> at 668; Ed Berkovich and Amy Kelly, FOIA'd CDC Emails Reveal Disturbing Myocarditis Timeline Warranting Investigation: Different Messaging Internally Vs. Publicly About COVID-19 Vaccines and Myocarditis, Daily Clout, Nov. 2, 2023, <https://dailyclout.io/foiad-cdc-emails-reveal-disturbing-myocarditis-timeline-warranting-investigation/>.

⁶ *Id.*

⁷ Biography, Tom Shimabukuro, M.D., Centers for Disease Control and Prevention, <https://blogs.cdc.gov/safehealthcare/bios/tom-shimabukuro/>.

Snapshot of March 4, 2021 heavily-redacted email⁸

From: Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP)
Sent: Thu, 4 Mar 2021 14:33:09 +0000
To: Miller, Elaine R. (CDC/DDID/NCEZID/DHQP)
Cc: Gallego, Ruth (CDC/DDID/NCEZID/DHQP); Su, John (CDC/DDID/NCEZID/DHQP)
Subject: RE: RESPONSE REQUIRED: Priority HIGH; Mode WebForm; Topic COVID-19 vaccine adverse events; [CDC-1460726-X0X9M8] CRM:09092401

Yes

From: Miller, Elaine R. (CDC/DDID/NCEZID/DHQP) <erm4@cdc.gov>
Sent: Thursday, March 4, 2021 9:29 AM
To: Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP) <ayv6@cdc.gov>
Cc: Gallego, Ruth (CDC/DDID/NCEZID/DHQP) <itd8@cdc.gov>; Su, John (CDC/DDID/NCEZID/DHQP) <ezu2@cdc.gov>
Subject: RE: RESPONSE REQUIRED: Priority HIGH; Mode WebForm; Topic COVID-19 vaccine adverse events; [CDC-1460726-X0X9M8] CRM:09092401

Tom,
[REDACTED]
[REDACTED]?

From: Miller, Elaine R. (CDC/DDID/NCEZID/DHQP)
Sent: Thursday, March 4, 2021 9:24 AM
To: Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP) <ayv6@cdc.gov>; Su, John (CDC/DDID/NCEZID/DHQP) <ezu2@cdc.gov>; Broder, Karen (CDC/DDID/NCEZID/DHQP) <krb2@cdc.gov>; Harrington, Theresa (CDC/DDID/NCEZID/DHQP) <tsh3@cdc.gov>; Dua, Anamika (CDC/DDID/NCEZID/DHQP) <qtv2@cdc.gov>
Cc: Gallego, Ruth (CDC/DDID/NCEZID/DHQP) <itd8@cdc.gov>
Subject: RE: RESPONSE REQUIRED: Priority HIGH; Mode WebForm; Topic COVID-19 vaccine adverse events; [CDC-1460726-X0X9M8] CRM:09092401

Thanks Tom

From: Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP) <ayv6@cdc.gov>
Sent: Thursday, March 4, 2021 9:17 AM
To: Miller, Elaine R. (CDC/DDID/NCEZID/DHQP) <erm4@cdc.gov>; Su, John (CDC/DDID/NCEZID/DHQP) <ezu2@cdc.gov>; Broder, Karen (CDC/DDID/NCEZID/DHQP) <krb2@cdc.gov>; Harrington, Theresa (CDC/DDID/NCEZID/DHQP) <tsh3@cdc.gov>; Dua, Anamika (CDC/DDID/NCEZID/DHQP) <qtv2@cdc.gov>
Cc: Gallego, Ruth (CDC/DDID/NCEZID/DHQP) <itd8@cdc.gov>
Subject: RE: RESPONSE REQUIRED: Priority HIGH; Mode WebForm; Topic COVID-19 vaccine adverse events; [CDC-1460726-X0X9M8] CRM:09092401


[REDACTED]

⁸ FOIA production: <https://childrenshealthdefense.org/wp-content/uploads/23-00056-for-2-24-2023-Close.pdf> at 668; FOIA code (b)(5) is used to protect inter-agency or intra-agency communications that are protected by legal privileges. *What information is available under the FOIA?* Dep't of Health & Hum. Servs., <https://www.hhs.gov/foia/faqs/what-information-is-available-under-the-foia/index.html> (last visited Nov. 19, 2024).

March 9, 2021 – March 10, 2021

Documents show that FDA and CDC officials began drafting “responses to the Israeli Ministry of Health’s inquiry.”⁹ On March 9, 2021, an FDA official emailed his “draft responses” to Dr. Shimabukuro, however, the email itself is almost completely redacted.

Snapshot of March 9, 2021 heavily-redacted email¹⁰



The next day, Dr. Shimabukuro emailed his CDC colleagues a document with the file name, “Myocarditis Response,” and wrote, “This is for that joint FDA-CDC to the Israeli [Ministry of Health]. Please let me know if you have any thoughts.”¹¹ Based on FOIA records, it appears that the document Dr. Shimabukuro shared with his colleagues was titled, “Summary of VAERS Reports of myocarditis, pericarditis and myopericarditis following vaccination with mRNA COVID-19 vaccines.”¹² The background section of the two-page document stated that it:

[R]esponds to questions posed from the Israeli Ministry of Health to the FDA and CDC. They are investigating a safety signal of myocarditis/myopericarditis in a younger population (16-30 years old) following administration of Pfizer-BioNTech Covid-19 vaccine. The Ministry of Health stated they received reports of around 40 cases of this adverse event. They did not provide additional details about these cases.¹³

The document included responses to four questions posed by the Israeli Ministry of Health and appears to be based on data obtained from “a search of the U.S. Vaccine Adverse Event Reporting System (VAERS) conducted on February 23, 2021[.]”¹⁴ That search apparently

⁹ *Id.* at 710.

¹⁰ *Id.*

¹¹ *Id.*; Ed Berkovich and Amy Kelly, FOIA’d CDC Emails Reveal Disturbing Myocarditis Timeline Warranting Investigation: Different Messaging Internally Vs. Publicly About COVID-19 Vaccines and Myocarditis, Daily Clout, Nov. 2, 2023, <https://dailyclout.io/foiad-cdc-emails-reveal-disturbing-myocarditis-timeline-warranting-investigation/>.

¹² FOIA production: <https://childrenshealthdefense.org/wp-content/uploads/23-00056-for-2-24-2023-Close.pdf> at 714.

¹³ *Id.*

¹⁴ *Id.*

revealed six cases of myocarditis, seven cases of myopericarditis, and 14 cases of pericarditis.”¹⁵
The document noted:

During this analysis period the reporting rate of myopericarditis following administration of the mRNA COVID-19 vaccines was low and estimated to be 0.7 per million doses of vaccine administered. However, the limitations of passive surveillance such as under-reporting, lack of a control group, missing and incomplete data make it challenging to assess causation. Thus, FDA has not made a final determination regarding the causality between myopericarditis and the mRNA COVID-19 vaccines. We will continue to monitor this outcome in active and passive surveillance.¹⁶

The document itself can be viewed in Enclosure 1. It remains unclear whether this document or another version of it was shared with the Israeli Ministry of Health. It is also unclear which FDA and CDC officials contributed to the document and when Israeli health officials shared that “they received reports of around 40 cases” of myocarditis/myopericarditis.¹⁷

March 15, 2021 – March 31, 2021

A collection of heavily-redacted FOIA records shows that on March 15, 2021, a CDC official who co-lead the Vaccine Safety Technical (VaST) Work Group began corresponding with an Israeli Ministry of Health official regarding “Covid-19 vaccine safety data.”¹⁸ On March 16, 2021, the Ministry official wrote, “[w]e will be happy to share our data” and later that day, the CDC official responded “[t]hank you for this note and for your willingness to present to VaST. We were hoping you could present on Monday, April 5.”¹⁹ Documents indicate that the Ministry official confirmed availability to present on April 5 and, on March 31, 2021, the CDC official requested that the Ministry official “send slides” ahead of the presentation.²⁰

According to a public report, the slides that the Israeli Ministry of Health provided to the CDC showed that “by the end of March 2021, 5.2 million Israelis received the first dose of the vaccine and 4.8 million received the second dose. The incidence of myocarditis following dose 1 was 1.1 per million, and 11.7 per million following dose 2 — a 964% increase in incidence between the two.”²¹ The slide deck can be viewed in Enclosure 4.

¹⁵ *Id.*

¹⁶ *Id.* at 715.

¹⁷ *Id.* at 714.

¹⁸ *Id.* at 726; Ed Berkovich and Amy Kelly, FOIA’d CDC Emails Reveal Disturbing Myocarditis Timeline Warranting Investigation: Different Messaging Internally Vs. Publicly About COVID-19 Vaccines and Myocarditis, Daily Clout, Nov. 2, 2023, <https://dailyclout.io/foiad-cdc-emails-reveal-disturbing-myocarditis-timeline-warranting-investigation/>.

¹⁹ FOIA production: <https://childrenshealthdefense.org/wp-content/uploads/23-00056-for-2-24-2023-Close.pdf> at 725.

²⁰ *Id.* at 721-722.

²¹ Brenda Baletti, Mounting Evidence Suggests CDC Hid Data on COVID Vaccines and Myocarditis, The Defender, Nov. 27, 2024, <https://childrenshealthdefense.org/defender/mounting-evidence-cdc-hid-data-covid-vaccines-myocarditis/>.

Snapshot of cover page of March 31, 2021 slide deck by Israeli Ministry of Health²²



April 5, 2021

Public reporting asserts that the slide deck from the Israeli Ministry of Health was included as an attachment in the CDC's April 5, 2021 agenda for the VaST meeting.²³ As shown below, the attachments and agenda for the meeting are heavily redacted:

²² FOIA production: <https://drive.google.com/file/d/1ywgzcxfpQI86lqslZPpYxylPuVnlgKfw/view> at 1.

²³ Brenda Baletti, Mounting Evidence Suggests CDC Hid Data on COVID Vaccines and Myocarditis, The Defender, Nov. 27, 2024, <https://childrenshealthdefense.org/defender/mounting-evidence-cdc-hid-data-covid-vaccines-myocarditis/>.

Snapshot of CDC's April 5, 2021 VaST meeting agenda

From: Markowitz, Lauri (CDC/DDID/NCIRD/DVD)
Sent: Mon, 5 Apr 2021 16:08:26 +0000
To: Anderson, Steven (FDA/CBER); Beresnev, Tatiana (NIH) [C]; Broder, Karen (CDC/DDID/NCEZID/DHQP); Calvert, Geoffrey M. (CDC/NIOSH/WTCHP); Clark, Matthew (IHS/ALB); Clark, Thomas A. (CDC/DDID/NCIRD/DVD); Cohn, Amanda (CDC/DDID/NCIRD/OD); Collins, Limone; [REDACTED] Daley, Matt; Destefano, Frank (CDC/DDID/NCEZID/DHQP); Dooling, Kathleen L. (CDC/DDID/NCIRD/DVD); Edwards, Kathy; Farizo, Karen (FDA/CBER); Forshee, Richard (FDA/CBER); Gee, Julianne (CDC/DDID/NCEZID/DHQP); Helfand, Rita (CDC/DDID/NCEZID/OD); Hiers, Susan G. (CDC/DDID/NCIRD/OD); Hopkins, Bob; Jackson, Lisa; Kelman, Jeffrey A. (CMS/CM); Kuldorf, Martin; LaPorte, Kathleen (CDC/DDID/NCIRD/ID); Lee, Grace; MacNeil, Jessica R. (CDC/DDID/NCIRD/OD); Markowitz, Lauri (CDC/DDID/NCIRD/DVD); Marquez, Paige L. (CDC/DDID/NCEZID/DHQP); Mbaeyi, Sarah (CDC/DDID/NCIRD/OD); Mullen, Jennifer (CDC/DDID/NCEZID/DHQP); Myers, Tanya R. (CDC/DDID/NCEZID/DHQP); Nair, Narayan (FDA/CBER); Oliver, Sara Elizabeth (CDC/DDID/NCIRD/DVD); Patricia Whitley-Williams (whitlepn@rwjms.rutgers.edu); Riley, Laura; Rubin, Mary (HRSA); Schechter, Robert; Shanley, Edwin (CDC/DDID/NCIRD/OD); Shay, David (CDC/DDID/NCIRD/ID); Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP); Sotir, Mark (CDC/DDID/NCIRD/DVD); Steinberg, Judith (HHS/OASH); Su, John (CDC/DDID/NCEZID/DHQP); Talbot, Keipp; Wasley, Annemarie (CDC/DDPHSIS/CGH/GID); Weintraub, Eric (CDC/DDID/NCEZID/DHQP); Wharton, Melinda (CDC/DDID/NCIRD/ISD); Wong, Hui-Lee (FDA/CBER); Woo, Jared (CDC/DDID/NCEZID/DHQP); Young, Mardia (CDC/DDID/NCEZID/DHQP) (CTR)
Subject: [EXTERNAL] VaST - Agenda for April 5 (1:30 - 3 pm ET) and presentations - CONFIDENTIAL

Attachments: [REDACTED] (b)(5)
[REDACTED] (b)(5)
2021_04_05 VaST Meeting Agenda.docx

Dear all,

This email includes the VaST agenda for today (below and attached) as well as 4 slide sets. The agenda attached has more information regarding approximate times for talks and discussion.

Agenda:
[REDACTED] (b)(5); (b)(6)

The VaST call link information should be on your calendars.
Reminder - all VaST documents and communications are confidential.

Lauri Markowitz and Melinda Wharton

Lauri Markowitz, MD
VaST Co-Lead
Division of Viral Diseases
National Center for Immunization and Respiratory Diseases

###

As a result of your agencies' excessive redactions and incomplete productions, the complete account of how your agencies reviewed and analyzed the concerning health information from the Israeli Ministry of Health remains unclear. Furthermore, my office has been informed that CDC completely redacted the March 31, 2021 slide deck in its FOIA production and that the slides were made available to the public through a State Department FOIA response.²⁴ Your agencies' lack of transparency is completely unacceptable. The public

²⁴ Brenda Baletti, Mounting Evidence Suggests CDC Hid Data on COVID Vaccines and Myocarditis, The Defender, Nov. 27, 2024, <https://childrenshealthdefense.org/defender/mounting-evidence-cdc-hid-data-covid-vaccines->

deserves the complete truth about your agencies' awareness of and lack of response to the glaring health risks associated with the COVID-19 vaccines. Accordingly, I request you provide the following information by no later than December 19, 2024:

1. An unredacted version of Enclosure 1.
 - a. All records²⁵ referring or relating to the drafting, review, and distribution of the attached document included and referenced in Enclosure 1.
2. An unredacted version of Enclosure 2.
3. An unredacted version of Enclosure 3.
4. All records referring or relating to Enclosure 4 including communications between and among agency employees regarding data from the Israeli Ministry of Health on adverse events following COVID-19 vaccination.
5. An unredacted version of Enclosure 5.

Thank you for your attention to this matter.

Sincerely,



Ron Johnson
Ranking Member
Permanent Subcommittee on Investigations

Enclosures

cc: The Honorable Richard Blumenthal
Chairman
Permanent Subcommittee on Investigations

The Honorable Christi Grimm
Inspector General
Department of Health and Human Services

myocarditis/; Letter from Brian Hooker, Chief Scientific Officer, Children's Health Defense, to Sen. Ron Johnson, Dec. 2, 2024 (on file with Subcomm.).

²⁵ "Records" include any written, recorded, or graphic material of any kind, including letters, memoranda, reports, notes, electronic data (emails, email attachments, and any other electronically-created or stored information), calendar entries, inter-office communications, meeting minutes, phone/voice mail or recordings/records of verbal communications, and drafts (whether or not they resulted in final documents).

Enclosure 1

From: Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP)
Sent: Wed, 10 Mar 2021 12:38:12 +0000
To: Su, John (CDC/DDID/NCEZID/DHQP); Broder, Karen (CDC/DDID/NCEZID/DHQP); Destefano, Frank (CDC/DDID/NCEZID/DHQP)
Subject: FW: [EXTERNAL] FW: Task ID: 42633 - HHS SOC RFI: Provide a Point of Contact to the Israeli National Focal Point to discuss Pfizer vaccine
Attachments: Myocarditis Response.docx

This is for that joint FDA-CDC to the Israeli MOH. Please let me know if you have any thoughts. Thanks.
Tom

From: Nair, Narayan <Narayan.Nair@fda.hhs.gov>
Sent: Tuesday, March 9, 2021 9:10 AM
To: Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP) <ayv6@cdc.gov>
Subject: RE: [EXTERNAL] FW: Task ID: 42633 - HHS SOC RFI: Provide a Point of Contact to the Israeli National Focal Point to discuss Pfizer vaccine

Hi Tom,

Here are some draft responses to the Israeli Ministry of Health's inquiry.

(b)(5)

(b)(5)

Narayan

From: Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP) <ayv6@cdc.gov>
Sent: Sunday, February 28, 2021 3:06 PM
To: Anderson, Steven <Steven.Anderson@fda.hhs.gov>; Forshee, Richard <Richard.Forshee@fda.hhs.gov>; Nair, Narayan <Narayan.Nair@fda.hhs.gov>
Subject: [EXTERNAL] FW: Task ID: 42633 - HHS SOC RFI: Provide a Point of Contact to the Israeli National Focal Point to discuss Pfizer vaccine

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

FYI.

From: Fitter, David L. (CDC/DDPHSIS/CGH/GID) <vid3@cdc.gov>
Sent: Sunday, February 28, 2021 2:28 PM
To: Martin, Stacey (CDC/DDID/NCEZID/DVBD) <zmt0@cdc.gov>; Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP) <ayv6@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Fox, Kimberley (CDC/DDID/NCIRD/DBD) <kaf6@cdc.gov>; Beauvais, Denise (CDC/DDID/NCIRD/OD) <cry2@cdc.gov>; CDC IMS 2019 NCOV Response VTF Policy <eocevent417@cdc.gov>; McClure, Susan (CDC/DDPHSIS/CGH/OD) <zur1@cdc.gov>

Subject: RE: Task ID: 42633 - HHS SOC RFI: Provide a Point of Contact to the Israeli National Focal Point to discuss Pfizer vaccine

Seeing that Denise is out. + Susan

Susan – can you please help coordinate?

Thanks,
-d

From: Fitter, David L. (CDC/DDPHSIS/CGH/GID)
Sent: Sunday, February 28, 2021 2:26 PM
To: Martin, Stacey (CDC/DDID/NCEZID/DVBD) <zmt0@cdc.gov>; Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP) <ayv6@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Fox, Kimberley (CDC/DDID/NCIRD/DBD) <kaf6@cdc.gov>; Beauvais, Denise (CDC/DDID/NCIRD/OD) <cry2@cdc.gov>; CDC IMS 2019 NCOV Response VTF Policy <eocevent417@cdc.gov>
Subject: RE: Task ID: 42633 - HHS SOC RFI: Provide a Point of Contact to the Israeli National Focal Point to discuss Pfizer vaccine

Thanks, Stacey.

(b)(5) ?

Best,
David

From: Martin, Stacey (CDC/DDID/NCEZID/DVBD) <zmt0@cdc.gov>
Sent: Sunday, February 28, 2021 1:35 PM
To: Fitter, David L. (CDC/DDPHSIS/CGH/GID) <vid3@cdc.gov>; Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP) <ayv6@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Fox, Kimberley (CDC/DDID/NCIRD/DBD) <kaf6@cdc.gov>
Subject: RE: Task ID: 42633 - HHS SOC RFI: Provide a Point of Contact to the Israeli National Focal Point to discuss Pfizer vaccine

Thanks David

(b)(5) ?

(b)(5)

From: Fitter, David L. (CDC/DDPHSIS/CGH/GID) <vid3@cdc.gov>
Sent: Sunday, February 28, 2021 11:15 AM
To: Martin, Stacey (CDC/DDID/NCEZID/DVBD) <zmt0@cdc.gov>; Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP) <ayv6@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Fox, Kimberley (CDC/DDID/NCIRD/DBD) <kaf6@cdc.gov>
Subject: FW: Task ID: 42633 - HHS SOC RFI: Provide a Point of Contact to the Israeli National Focal Point to discuss Pfizer vaccine
Importance: High

Stacey and Tom,

Please see below re discussing with Israeli Vaccine FP re myocarditis in people receiving Pfizer vaccine.

Thanks,
David

From: CDC IMS Task Tracker (CDC) <eoctasktracker@cdc.gov>
Sent: Sunday, February 28, 2021 1:13 PM
To: CDC IMS 2019 NCOV Response VTF Vaccine Safety <eocevent416@cdc.gov>; CDC IMS 2019 NCOV Response VTF Policy <eocevent417@cdc.gov>; CDC IMS 2019 NCOV Response VTF Chief Medical Officer <eocevent516@cdc.gov>; CDC IMS 2019 NCOV Response VTF Operations <eocvtftask@cdc.gov>
Cc: CDC IMS Task Tracker (CDC) <eoctasktracker@cdc.gov>; Fox, Kimberley (CDC/DDID/NCIRD/DBD) <kaf6@cdc.gov>; Fitter, David L. (CDC/DDPHSIS/CGH/GID) <vid3@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>
Subject: Task ID: 42633 - HHS SOC RFI: Provide a Point of Contact to the Israeli National Focal Point to discuss Pfizer vaccine
Importance: High

Task ID: 42633

Suspense: 3/2/2021 17:00:00

Assigned To: CDC IMS 2019 NCOV Response VTF Chief Medical Officer, CDC IMS 2019 NCOV Response VTF Operations, CDC IMS 2019 NCOV Response VTF Policy, CDC IMS 2019 NCOV Response VTF Vaccine Safety

Requestor's Name: Dr. Roe Singer MD, MPH (b)(6)

Phone #: (b)(6)

Subject: HHS SOC RFI: Provide a Point of Contact to the Israeli National Focal Point to discuss Pfizer vaccine

Description: The Israeli National Focal Point is noticing a large number of reports of myocarditis, particularly in young people, following the administration of the Pfizer vaccine. The

Israeli National Focal Point is requesting a Point of Contact from the CDC and FDA to discuss the issue..

Please coordinate with the appropriate IMS Desk(s) and provide coordinated response to the requestor by the suspense. If clarification on the task is required, please contact the requestor. Reply back to this email noting that you have completed this task.

Please include the original task ID number in the email. **The subject line should include Event Name, Task #, Team Name and "Open Task" or "Close Task".**

Summary of VAERS Reports of myocarditis, pericarditis and myopericarditis following vaccination with mRNA COVID-19 vaccines

Background:

This memo responds to questions posed from the Israeli Ministry of Health to the FDA and CDC. They are investigating a safety signal of myocarditis /myopericarditis in a younger population (16 -30 years old) following administration of Pfizer-BioNTech Covid-19 vaccine. The Ministry of Health stated they received reports of around 40 cases of this adverse event. They did not provide additional details about these cases.

Questions Posed by Israeli Ministry of Health:

1. How many doses of the vaccine were administered to this age group?

CDC to provide this data

2. How many cases of myocarditis / peri-myocarditis were reported in your country?

A search of the U.S. Vaccine Adverse Event Reporting System (VAERS) conducted on February 23, 2021 revealed 27 cases (6 cases of myocarditis, 7 cases of myopericarditis, 14 cases pericarditis).

The following Medical Dictionary for Regulatory Activities (MedDRA) preferred terms were used to conduct the search: myocarditis; eosinophilic myocarditis; hypersensitivity myocarditis; pericarditis; pericarditis adhesive; pericarditis constrictive; pleuropericarditis; pericardial disease; pericardial effusion; pericardial rub; myopericarditis. Reports with sufficient information were reviewed and categorized based on case definitions previously used for surveillance of myopericarditis after smallpox vaccine (<https://www.cdc.gov/mmwr/PDF/wk/mm5221.pdf>).

Reports were included if they contained a diagnosis by of myocarditis, pericarditis or myopericarditis. Reports with pericardial effusion and no other signs of myopericarditis were excluded. If the diagnosis in the narrative was pericarditis but the patient also had elevated troponin they were categorized as myopericarditis.

3. Could you elaborate details on these AE cases (time of diagnosis from the vaccine, first/second dose, risk factors, etc.) ?

Twelve cases occurred after dose 1, 7 cases after dose 2, and the dose was not reported for 8 cases. Four patients had comorbid conditions that could suggest alternate etiologies for the adverse event. These included:

- One patient with subacute pericarditis noted on cardiac MRI. The clinical impression was this pre-dated vaccination
- One patient had a history of recurrent pericarditis
- One patient had recent SARS CoV-2 infection
- One patient had psoriatic arthritis and was on Adalimumab

None of the cases reported other risk factors or causes such as preceding viral infections or other vaccines administered concurrently. However, due to the nature of passive surveillance reports, it is not possible to completely exclude these due to potential incompleteness of reports.

The following table displays additional information about the cases of myopericarditis.

Characteristics	Reports of Myopericarditis/Myocarditis/Pericarditis (N = 27)
Median age, years (range)*	36 (21–84)
Female (%)	10(37)
Male (%)	16 (59)
Gender not reported (%)	1(4)
Median Time to Onset in Days (range)	3 (0-20)

4. Have you assessed the causality between the AE and the vaccine for each of the cases?

During this analysis period the reporting rate of myopericarditis following administration of the mRNA COVID-19 vaccines was low and estimated to be 0.7 per million doses of vaccine administered. However, the limitations of passive surveillance such as under-reporting, lack of a control group, missing and incomplete data make it challenging to assess causation. Thus, FDA has not made a final determination regarding the causality between myopericarditis and the mRNA COVID-19 vaccines. We will continue to monitor this outcome in active and passive surveillance.

Enclosure 2

From: Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP)
Sent: Thu, 4 Mar 2021 14:33:09 +0000
To: Miller, Elaine R. (CDC/DDID/NCEZID/DHQP)
Cc: Gallego, Ruth (CDC/DDID/NCEZID/DHQP); Su, John (CDC/DDID/NCEZID/DHQP)
Subject: RE: RESPONSE REQUIRED: Priority HIGH; Mode WebForm; Topic COVID-19 vaccine adverse events; [CDC-1460726-X0X9M8] CRM:09092401

Yes

From: Miller, Elaine R. (CDC/DDID/NCEZID/DHQP) <erm4@cdc.gov>
Sent: Thursday, March 4, 2021 9:29 AM
To: Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP) <ayv6@cdc.gov>
Cc: Gallego, Ruth (CDC/DDID/NCEZID/DHQP) <ltld8@cdc.gov>; Su, John (CDC/DDID/NCEZID/DHQP) <ezu2@cdc.gov>
Subject: RE: RESPONSE REQUIRED: Priority HIGH; Mode WebForm; Topic COVID-19 vaccine adverse events; [CDC-1460726-X0X9M8] CRM:09092401

Tom,

(b)(5)

(b)(5)

From: Miller, Elaine R. (CDC/DDID/NCEZID/DHQP)
Sent: Thursday, March 4, 2021 9:24 AM
To: Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP) <ayv6@cdc.gov>; Su, John (CDC/DDID/NCEZID/DHQP) <ezu2@cdc.gov>; Broder, Karen (CDC/DDID/NCEZID/DHQP) <krb2@cdc.gov>; Harrington, Theresa (CDC/DDID/NCEZID/DHQP) <tsh3@cdc.gov>; Dua, Anamika (CDC/DDID/NCEZID/DHQP) <qtv2@cdc.gov>
Cc: Gallego, Ruth (CDC/DDID/NCEZID/DHQP) <ltld8@cdc.gov>
Subject: RE: RESPONSE REQUIRED: Priority HIGH; Mode WebForm; Topic COVID-19 vaccine adverse events; [CDC-1460726-X0X9M8] CRM:09092401

Thanks Tom

From: Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP) <ayv6@cdc.gov>
Sent: Thursday, March 4, 2021 9:17 AM
To: Miller, Elaine R. (CDC/DDID/NCEZID/DHQP) <erm4@cdc.gov>; Su, John (CDC/DDID/NCEZID/DHQP) <ezu2@cdc.gov>; Broder, Karen (CDC/DDID/NCEZID/DHQP) <krb2@cdc.gov>; Harrington, Theresa (CDC/DDID/NCEZID/DHQP) <tsh3@cdc.gov>; Dua, Anamika (CDC/DDID/NCEZID/DHQP) <qtv2@cdc.gov>
Cc: Gallego, Ruth (CDC/DDID/NCEZID/DHQP) <ltld8@cdc.gov>
Subject: RE: RESPONSE REQUIRED: Priority HIGH; Mode WebForm; Topic COVID-19 vaccine adverse events; [CDC-1460726-X0X9M8] CRM:09092401

(b)(5)

From: Miller, Elaine R. (CDC/DDID/NCEZID/DHQP) <erm4@cdc.gov>
Sent: Thursday, March 4, 2021 8:52 AM
To: Su, John (CDC/DDID/NCEZID/DHQP) <ezu2@cdc.gov>; Broder, Karen (CDC/DDID/NCEZID/DHQP) <krb2@cdc.gov>; Harrington, Theresa (CDC/DDID/NCEZID/DHQP) <tsh3@cdc.gov>; Dua, Anamika (CDC/DDID/NCEZID/DHQP) <qtv2@cdc.gov>; Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP) <ayv6@cdc.gov>
Cc: Gallego, Ruth (CDC/DDID/NCEZID/DHQP) <ltd8@cdc.gov>
Subject: RE: RESPONSE REQUIRED: Priority HIGH; Mode WebForm; Topic COVID-19 vaccine adverse events; [CDC-1460726-X0X9M8] CRM:09092401

Hi all,

(b)(5)

Is anyone able to talk to this MD from the Israel Ministry of Health?

Thanks,
Elaine

From: CDC IMS 2019 NCOV COVID Vaccine Inquiry Management
Sent: Wednesday, March 3, 2021 8:31:15 PM (UTC-05:00) Eastern Time (US & Canada)
To: CDC IMS 2019 NCOV Response VTF Global
Cc: COVID19VaxSafety; CISA Response (CDC); CDC IMS 2019 NCOV Response VTF Communications; CDC IMS 2019 NCOV Response International Task Force
Subject: Fw: RESPONSE REQUIRED: Priority HIGH; Mode WebForm; Topic COVID-19 vaccine adverse events; [CDC-1460726-X0X9M8] CRM:09092401

Hello VTF Global colleagues,

Please see the inquiry from the Deputy Director, Division of Epidemiology, MoH Israel below. Could you please respond?

Thank you,

Kate

(b)(5)

COVID-19 Vaccine Clinical Inquiries Management Team | Vaccine Task Force
CDC Coronavirus Disease 2019 (COVID-19) Response | eocevent168@cdc.gov

Further CDC Resources:

[COVID-19 What's New](#)

[CDC Health Alert Network \(HAN\)](#)

[CDC Vaccines](#)

[CDC Clinician Outreach and Communication Activity \(COCA\)](#)

From: CDCInfoResponse <cdcinforesponse@cdcinqury.onmicrosoft.com>

Sent: Wednesday, March 3, 2021 1:50 PM

To: CDC IMS 2019 NCOV COVID Vaccine Inquiry Management <eocevent168@cdc.gov>

Subject: RESPONSE REQUIRED: Priority HIGH; Mode WebForm; Topic COVID-19 vaccine adverse events; [CDC-1460726-X0X9M8] CRM:09092401

Please let us know if you are able to respond to this inquiry or if you would like us to forward the inquiry to another program. This inquiry is being escalated because the answer could not be found in CDC resources.

To close the case, you may reply directly to this e-mail, keeping the original subject line and historical e-mail thread in your reply. Please let us know if your group will provide the answer directly to the inquirer below, or provide a reply for us to send back.

To better serve the inquirer, please reply within 3 business days of receipt of this escalation. A reminder will be sent in 8 days; the inquiry will be closed after 10 days.

Thank you for your assistance.

OO/PR#14312/17771/11109

The privacy of the inquirer should be protected in any transmission or storage of this e-mail.

----- Original Message-----

Sent: 3/3/2021

From: Clinician

Subject: COVID-19 vaccine adverse events

Email Address: (b)(6)

Question: From the Israel vaccine adverse event monitoring team:

We are seeing a large number of myocarditis and pericarditis cases in young individuals soon after Pfizer COVID-19 vaccine. We would like to discuss the issue with a relevant expert at CDC.

Optional Information

Name: Dr. Roe Singer

Title: Deputy Director, Division of Epidemiology, MoH Israel

Organization: SLHD - Israel Ministry of Health

Phone: (b)(6)

Other Email: (b)(6)

Address:

Jerusalem, Israel

PII Extraction:

Enclosure 3

From: Wharton, Melinda (CDC/DDID/NCIRD/ISD)
Sent: Thu, 1 Apr 2021 13:32:47 +0000
To: Markowitz, Lauri (CDC/DDID/NCIRD/DVD)
Subject: RE: Covid-19 vaccine safety data

(b)(5)

From: Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>
Sent: Thursday, April 1, 2021 9:04 AM
To: Wharton, Melinda (CDC/DDID/NCIRD/ISD) <mew2@cdc.gov>
Subject: RE: Covid-19 vaccine safety data

(b)(5)

From: Wharton, Melinda (CDC/DDID/NCIRD/ISD) <mew2@cdc.gov>
Sent: Thursday, April 1, 2021 9:00 AM
To: Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>
Subject: RE: Covid-19 vaccine safety data

(b)(5)

(b)(5)

From: Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>
Sent: Thursday, April 1, 2021 8:57 AM
To: Wharton, Melinda (CDC/DDID/NCIRD/ISD) <mew2@cdc.gov>
Subject: FW: Covid-19 vaccine safety data

Melinda,

(b)(5)

Lauri

This is the schedule – (b)(5)

(b)(5)

(b)(5)

From: מ'ר עמיליה אניס <EMILIA.ANIS@MOH.GOV.IL>
Sent: Thursday, April 1, 2021 4:24 AM
To: Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>
Cc: מ'ר עמיליה אניס <hadas.rotem@MOH.GOV.IL>; מ'ר עמיליה אניס <BOAZ.LEV@MOH.GOV.IL>; מ'ר עמיליה אניס <dana.arad@MOH.GOV.IL>; מ'ר עמיליה אניס <sharon.alroy@MOH.GOV.IL>
Subject: RE: Covid-19 vaccine safety data

Dear Laurie,

I think we will need another 5-10 minutes for our presentation.

We prefer to have these discussions by zoom. Will your invitation be by zoom or would you prefer us to send?

Regards,



Emilia Anis, MD, MPH
Director
Division of Epidemiology
Ministry of Health, Israel
Tel. 972-2-5080521
Fax: 972-2-5655950
Mobile: 972-50-6242145
E-mail: emilia.anis@moh.health.gov.il

From: Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>
Sent: Wednesday, March 31, 2021 7:20 PM
To: מ'ר עמיליה אניס <EMILIA.ANIS@MOH.GOV.IL>
Cc: מ'ר עמיליה אניס <hadas.rotem@MOH.GOV.IL>; מ'ר עמיליה אניס <BOAZ.LEV@MOH.GOV.IL>; מ'ר עמיליה אניס <dana.arad@MOH.GOV.IL>; מ'ר עמיליה אניס <sharon.alroy@MOH.GOV.IL>
Subject: RE: Covid-19 vaccine safety data

Dear Emilia,

For the VaST call next Monday, April 5, you will receive a calendar invitation from the VaST call scheduler either on Friday this week or on Monday morning.

We have several items on the agenda and would like the presentation from Israel to be first. We have scheduled 15 minutes for the presentation and 10 minutes for discussion. Will 15 minutes be enough time? It would be great if you can send slides to me before Monday, but if not, Monday morning is OK.

Regards,
Lauri

Lauri Markowitz, MD
VaST Co-Lead
Division of Viral Diseases
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention

From: Markowitz, Lauri (CDC/DDID/NCIRD/DVD)
Sent: Wednesday, March 24, 2021 12:17 PM
To: 'ד"ר עמיליה אניס' <EMILIA.ANIS@MOH.GOV.IL>
Cc: Wharton, Melinda (CDC/DDID/NCIRD/ISD) <mew2@cdc.gov>; ד"ר חדס רוטם <hadas.rotem@MOH.GOV.IL>; ד"ר בואז לזב <BOAZ.LEV@MOH.GOV.IL>; ד"ר דנה ארד <dana.arad@MOH.GOV.IL>; ד"ר שרון אלרוי <sharon.alroy@MOH.GOV.IL>; Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP) <ayv6@cdc.gov>
Subject: RE: Covid-19 vaccine safety data

Dear Emilia,

Thank you for confirming that the time will work for you to present to VaST on April 5.

(b)(5)

(b)(5)

I'm also Cc'ing Dr. Tom Shimabukuro who is the vaccine safety team lead on the CDC COVID-19 Vaccine Task Force who can provide additional information, if needed.

Lauri Markowitz, MD

VaST Co-Lead

Division of Viral Diseases

National Center for Immunization and Respiratory Diseases

Centers for Disease Control and Prevention

From: א'ר ארררר אררררררר <EMILIA.ANIS@MOH.GOV.IL>

Sent: Monday, March 22, 2021 12:51 PM

To: Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>

Cc: Wharton, Melinda (CDC/DDID/NCIRD/ISD) <mew2@cdc.gov>; ארררר ארר
<hadas.rotem@MOH.GOV.IL>; אר אררר <BOAZ.LEV@MOH.GOV.IL>; ארר אררר <dana.arad@MOH.GOV.IL>;
אררררר אררררר ארררר <sharon.alroy@MOH.GOV.IL>

Subject: RE: Covid-19 vaccine safety data

Dear Lauri,

(b)(5)

Best regards,



Emilia Anis, MD, MPH
Director
Division of Epidemiology
Ministry of Health, Israel
Tel. 972-2-5080521
Fax: 972-2-5655950
Mobile: 972-50-6242145
E-mail: emilia.anis@moh.health.gov.il

From: א'רן רוטמן [mailto:arn@mo.gov.il]
Sent: Saturday, March 20, 2021 4:18 PM
To: 'Markowitz, Lauri (CDC/DDID/NCIRD/DVD)' <lem2@cdc.gov>
Cc: Wharton, Melinda (CDC/DDID/NCIRD/ISD) <mew2@cdc.gov>; אהוד רוטמן
<hadas.rotem@MOH.GOV.IL>; אבנר לוי <BOAZ.LEV@MOH.GOV.IL>; דנה ארד <dana.arad@MOH.GOV.IL>;
אמיליה אניס [mailto:emilia.anis@moh.health.gov.il] <emilia.anis@moh.health.gov.il>
Subject: RE: Covid-19 vaccine safety data

Dear Lauri,

I will check with my colleagues and get back to you tomorrow.

Best regards,



Emilia Anis, MD, MPH
Director
Division of Epidemiology
Ministry of Health, Israel
Tel. 972-2-5080521
Fax: 972-2-5655950
Mobile: 972-50-6242145
E-mail: emilia.anis@moh.health.gov.il

From: Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>
Sent: Tuesday, March 16, 2021 11:48 PM
To: א'רן רוטמן [mailto:arn@mo.gov.il] <EMILIA.ANIS@MOH.GOV.IL>
Cc: Wharton, Melinda (CDC/DDID/NCIRD/ISD) <mew2@cdc.gov>; אהוד רוטמן
<hadas.rotem@MOH.GOV.IL>; אבנר לוי <BOAZ.LEV@MOH.GOV.IL>; דנה ארד <dana.arad@MOH.GOV.IL>;

????? ?????? ??????<sharon.alroy@MOH.GOV.IL>

Subject: RE: Covid-19 vaccine safety data

Dear Dr. Anis,

Thank you for this note and for your willingness to present to VaST. We were hoping you could present on Monday, April 5. Our calls are at 1:30 PM EDT. I know this is the early evening in Jerusalem, so let me know if this will work of you.

Warm regards,
Lauri

Lauri Markowitz, MD

VaST Co-Lead

Division of Viral Diseases

National Center for Immunization and Respiratory Diseases

Centers for Disease Control and Prevention

From: ?' ? ???? ??????<EMILIA.ANIS@MOH.GOV.IL>

Sent: Tuesday, March 16, 2021 9:28 AM

To: Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>

Cc: Wharton, Melinda (CDC/DDID/NCIRD/ISD) <mew2@cdc.gov>; ????? ????
<hadas.rotem@MOH.GOV.IL>; ?? ????<BOAZ.LEV@MOH.GOV.IL>; ??? ????<dana.arad@MOH.GOV.IL>;
????? ?????? ??????<sharon.alroy@MOH.GOV.IL>

Subject: RE: Covid-19 vaccine safety data

Dear Dr. Markowitz,

Thank you for the invitation.

We will be happy to share our data. Please let us know enough time in advance and note that there are Passover holidays from 27.3 until 3.4.

Best regards from Jerusalem,



Emilia Anis, MD, MPH
Director

Division of Epidemiology
Ministry of Health, Israel
Tel. 972-2-5080521
Fax: 972-2-5655950
Mobile: 972-50-6242145
E-mail: emilia.anis@moh.health.gov.il

From: Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>
Sent: Monday, March 15, 2021 4:06 PM
To: ד"ר אמיליה אניס <EMILIA.ANIS@MOH.GOV.IL>
Cc: Wharton, Melinda (CDC/DDID/NCIRD/ISD) <mew2@cdc.gov>
Subject: Covid-19 vaccine safety data

Dear Dr. Emilia Anis,

I am writing to inquire

(b)(5)

(b)(5)

Thank you and I hope all is well there,
Lauri

Lauri Markowitz, MD

VaST Co-Lead

Division of Viral Diseases

National Center for Immunization and Respiratory Diseases

Centers for Disease Control and Prevention

1600 Clifton Rd MS H24-5

Atlanta, GA 30329-4027

Phone: 404-639-8359

Cell: 404-384-3767

Email: lem2@cdc.gov

Enclosure 4

Adverse events following vaccination COVID-19

Data updated March 31st 2021



Division of Epidemiology
Public health services
Ministry of Health Israel

Sources of adverse events reports



Sources of adverse events reports include:

- Hospitals
- HMOs
- Emergency Medical Services - MDA (for individuals who are vaccinated in nursing homes)
- The Medical Department and the Patient Safety Unit at the MoH
- Israeli Defense Forces (IDF)




Vaccine doses administered in Israel

R-2024-00044 A-00000749473 "UNCLASSIFIED" 11/21/2024



Vaccine doses administered in Israel (cumulative)






Distribution of vaccine recipients according to age



Distribution of vaccine recipients in Israel according to age



AgeGroup	16-19	20-29	30-39	40-49	50-59	60-69	70-79	80-89	90<
Vaccine coverage by age group 1 st dose	55.3%	72.9%	77.6%	82.3%	87.2%	88.7%	97.3%	94.6%	97.4%
Vaccine coverage by age group 2 nd dose	47.0%	63.2%	69.5%	75.7%	81.1%	84.2%	93.7%	90.8%	91.7%




Age and sex distribution among vaccine recipients and those who reported adverse events - FIRST DOSE




R-2024-00044 A-00000749473 "UNCLASSIFIED" 11/21/2024

Distribution according to age group and sex among recipients of first vaccine dose.



Distribution according to age group and sex among individuals reporting adverse events following first dose vaccination.




Women and younger individuals are more likely to report adverse reactions following vaccination relative to their proportion among the vaccine recipient population




Age and sex distribution among vaccine recipients and those who reported adverse events - SECOND DOSE

Distribution according to age group and sex among recipients of second vaccine dose.





Distribution according to age group and sex among individuals reporting adverse events following second dose vaccination



Women and younger individuals are more likely to report adverse reactions following vaccination relative to their proportion among the vaccine recipient population



Adverse events following vaccination by category



Reports among vaccine recipients
1st dose: 5,244,481 2nd dose: 4,785,534

Updated 31/03/2021




R-2024-00044 A-00000749473 "UNCLASSIFIED" 11/21/2024

Local reactions




Local reactions (at injection site) reported following vaccination, rate per million doses- first dose



Rate per million vaccine doses out of 5,244,481 vaccine 1st dose recipients

Local reactions (at injection site) reported following vaccination, rate per million doses- second dose



Rate per million vaccine doses out of 4,785,534 vaccine 2nd dose recipients

Updated 31/03/2021



R-2024-00044

A-00000749473


"UNCLASSIFIED"

11/21/2024

Systemic reactions




General reactions reported following immunization, rate per million doses- first dose



Rate per million vaccine doses out of 5,244,481 vaccine 1st dose recipients

General reactions reported following immunization, rate per million doses- second dose



Rate per million vaccine doses out of 4,785,534 vaccine 2nd dose recipients

Updated 31/03/2021



R-2024-00044

A-00000749473


"UNCLASSIFIED"

11/21/2024

Allergic reactions




Allergic reactions reported following vaccination, rate per million vaccine doses- first dose



Rate per million vaccine doses out of 5,244,481 vaccine 1st dose recipients

Allergic reactions reported following vaccination, rate per million vaccine doses- second dose



Rate per million vaccine doses out of 4,785,534 vaccine 2nd dose recipients

Updated 31/03/2021

Neurologic reactions




Number of neurologic reactions reported

	Numbness/ Parasthesia	Facial nerve palsy	Other neurologic reactions	Metal or bitter taste in mouth	Seizure (focal or generalized)	Loss of consciousness	Transian ischemic attack
1 st dose	350	64	48	18	18	12	7
2 nd dose	178	26	25	13	8	7	2

Rate of neurological reactions reported following vaccination

Rate per million doses vaccine



Updated 31/03/2021

Data is based on adverse events reported to the MoH | Some individuals reported more than one adverse event



R-2024-00044

A-00000749473

"UNCLASSIFIED"

11/21/2024

Neurologic reactions



		Bell's palsy (1 case pregnant)		Blurred vision		Sudden sensorineural hearing loss		Abducens nerve palsy		Vertigo		Occulomotor nerve palsy		Trigeminal neuralgia		Seizures		Transient Ischemic Attack		Guillain Barré syndrome (1 case exacerbation)		Multiple sclerosis (1 case exacerbation, 1 new case)		Brachial plexitis		
		1 st dose	2 nd dose	1 st dose	2 nd dose	1 st dose	2 nd dose	1 st dose	2 nd dose	1 st dose	2 nd dose	1 st dose	2 nd dose	1 st dose	2 nd dose	1 st dose	2 nd dose	1 st dose	2 nd dose	1 st dose	2 nd dose	1 st dose	2 nd dose	1 st dose	2 nd dose	
Age group	<20	1	1													2	1									
	20-29	3	2		1	1								1		2	1	1		1						
	30-39	7	2	3		1	1									2	1									
	40-49	13	5	2	3		2			1						1	5	1				1				
	50-59	11	10	6	1	2	1				1					2				1						
	60-69	16	4	2		1	1	1	1	1	2	1				1		1		1	1			1		
	70-79	9	2			1			1							4		1	1	1		1				
	80-89	4				1	2		1							4		3								
	>90																		1							
	Total	64	26	13	5	7	7	1	3	2	3	1		1		18	8	7	2	4	1	2		1		
Follow-up second dose	38	Not relevant	10	Not relevant	5	Not relevant	1	Not relevant	0	Not relevant	1	Not relevant	1	Not relevant	12	Not relevant	6	Not relevant	1	Not relevant	2	Not relevant	1	Not relevant		
Expected number of cases in population age 16 and older, for same time period of vaccination project and same population group	168	128	51	39	180	135	41	30	465	341	17	12	41	31	1372	1018	1258	920	139	110	334	260	13	9		

The observed numbers are compared to the morbidity data in hospitalized patients from 2017-2019 which includes morbidity data reported among all individuals 16 years and older from the corresponding periods – *i.e.* morbidity cases following the first and second dose is compared to morbidity cases in hospitalized patients from December - March and January - March respectively.

NOTE: In addition to the data presented in the table, the MoH monitors other reactions for which expected numbers cannot be presented.

Updated 31/03/2021

Data is based on adverse events reported to the MoH | Some individuals reported more than one adverse event



Other adverse events of interest

Other AEs of interest following vaccination (rate per million vaccine doses) compared to expected rates in the general population according to morbidity data from the corresponding periods of years 2017-2019

Other adverse events of interest	Medical diagnosis	AE rates following first dose (Dec-Mar)	Expected rates (hospitalization data Dec-Mar 2017-2019)	AE rates following second dose (Jan-Mar)	Expected rates (hospitalization data Jan-Mar 2017-2019)
Hematological	Thrombocytopenia	0.6	26.9	0.4	21.0
	Purpura	0.2	21.2	Not reported	15.2
Infections	Sepsis	0.2	71.1	Not reported	53.5
	Herpes zoster	3.4	44.2	3.6	33.4
	Herpes simplex	1.3	15.2	1.3	10.5
	Necrotizing Fasciitis	0.2	6.5	Not reported	4.8
Neurological	Transient Ischemic Attack	1.3	201.8	0.4	147.6
	Encephalitis	0.2	1.4	Not reported	1.1
	Diplopia (double vision)	0.4	9.3	0.6	6.8
	Acute hearing loss	1.3	28.9	1.5	21.6
	Shoulder weakness and severe pain	0.2	2.1	Not reported	1.5
	Facial weakness and severe pain	0.2	6.6	Not reported	5.0
	Blurred vision	2.5	8.2	1.0	6.3
	Vertigo	0.4	59.7	0.6	43.3
	Guillain barre syndrome	0.8	22.3	0.2	17.7

Note: Despite normalization to the number of vaccinees, observed and expected rates cannot be directly compared, because the observed cases are counted differently than the expected ones. The observed cases count morbidity within a time window of a defined event (vaccine administration). The expected cases are calculated by the cumulative incidence over several calendar months. However, the expected cases do give a general order of magnitude for comparison of morbidity following vaccine administration.

The observed rates are compared to the morbidity data in hospitalized patients from 2017-2019 which includes morbidity data reported among all individuals 16 years and older from the corresponding periods – *i.e.* morbidity rates following the first and second dose is compared to morbidity rates in hospitalized patients from December - March and January - March respectively.

NOTE: In addition to the data presented in the table, the MoH monitors other reactions for which expected rates cannot be presented.



Other adverse events of interest

Other AEs of interest following vaccination (rate per million vaccine doses) compared to expected rates in the general population according to morbidity data from the corresponding periods of years 2017-2019

Other adverse events of interest	Medical diagnosis	AE rates following first dose (Dec-Mar)	Expected rates (hospitalization data Dec-Mar 2017-2019)	AE rates following second dose (Jan-Mar)	Expected rates (hospitalization data Jan-Mar 2017-2019)
Cardiovascular	Myocardial infarction	0.6	746.1	0.2	554.1
	Heart failure	0.4	859.2	Not reported	648.6
	Subarachnoid hemorrhage	0.2	19.9	Not reported	14.2
	Vasculitis	Not reported	7.3	0.2	4.5
	Pericarditis	1.0	48.7	2.1	36.6
	Myocarditis (including Perimyocarditis)	1.1	21.3	11.7	15.6
	Cardiac tamponade	0.2	3.8	Not reported	2.5
	Venous thrombosis (DVT)	Not reported	65.2	0.6	48.1
	Superficial venous thrombosis	Not reported	3.6	0.2	2.7
	Atrial Fibrillation	0.4	560.4	0.6	414.3
	Stroke	1.0	649.1	0.2	475.6
	Pulmonary embolism	0.2	78.0	0.2	56.4
	Pericardial effusion	0.4	33.9	0.2	26.8
Ophthalmological	Retinopathy	0.2	0.8	Not reported	0.5
Rheumatology	Arthritis	Not reported	252.7	0.2	191.6

Note: Despite normalization to the number of vaccinees, observed and expected rates cannot be directly compared, because the observed cases are counted differently than the expected ones. The observed cases count morbidity within a time window of a defined event (vaccine administration). The expected cases are calculated by the cumulative incidence over several calendar months. However, the expected cases do give a general order of magnitude for comparison of morbidity following vaccine administration.

The observed rates are compared to the morbidity data in hospitalized patients from 2017-2019 which includes morbidity data reported among all individuals 16 years and older from the corresponding periods – *i.e.* morbidity rates following the first and second dose is compared to morbidity rates in hospitalized patients from December - March and January - March respectively.

NOTE: In addition to the data presented in the table, the MoH monitors other reactions for which expected rates cannot be presented.



Other adverse events of interest

Other AEs of interest following vaccination (rate per million vaccine doses) compared to expected rates in the general population according to morbidity data from the corresponding periods of years 2017-2019

Other adverse events of interest	Medical diagnosis	AE rates following first dose (Dec-Mar)	Expected rates (hospitalization data Dec-Mar 2017-2019)	AE rates following second dose (Jan-Mar)	Expected rates (hospitalization data Jan-Mar 2017-2019)
Pregnant (rate calculated out of women ages 16-49 whom received the vaccine)	Missed abortion	1.3	1909.4	Not reported	1473.1
	IUFD	1.3	71.6	Not reported	53.8
	CMV	Not reported	3.8	0.7	3.2
Respiratory	Pleuritis	0.2	2.4	Not reported	1.7
	Pulmonary edema	Not reported	259.8	0.2	196.0
	Severe acute respiratory syndrome	Not reported	177.5	0.2	132.9
Organ damage	Acute liver damage	0.2	3.9	Not reported	2.8
	Acute kidney damage	0.2	227.4	Not reported	168.7
Other	Erythema Multiforme	0.2	3.4	Not reported	2.6
	Loss of smell (anosmia)/loss of taste (ageusia)	1.3	1.8	1.0	1.2
	Appendicitis	Not reported	315.9	0.2	235.3
	Acute thyroiditis	Not reported	2.4	0.2	1.9
	Multiple sclerosis (1 relapse and 1 new diagnosis)	0.4	53.6	Not reported	41.8
	Hemorrhagic cystitis	0.2	4.9	Not reported	3.9
rhabdomyolysis	Not reported	20.6	0.2	16.0	

Note: Despite normalization to the number of vaccinees, observed and expected rates cannot be directly compared, because the observed cases are counted differently than the expected ones. The observed cases count morbidity within a time window of a defined event (vaccine administration). The expected cases are calculated by the cumulative incidence over several calendar months. However, the expected cases do give a general order of magnitude for comparison of morbidity following vaccine administration.

The observed rates are compared to the morbidity data in hospitalized patients from 2017-2019 which includes morbidity data reported among all individuals 16 years and older from the corresponding periods – *i.e* morbidity rates following the first and second dose is compared to morbidity rates in hospitalized patients from December - March and January - March respectively.

NOTE: In addition to the data presented in the table, the MoH monitors other reactions for which expected rates cannot be presented.



Myocarditis following vaccination

To date, 62 cases of myocarditis following vaccination have been reported

Myocarditis after first dose (N=6)

- 4 males, 2 females
- 1 case myocarditis, 5 cases of Perimyocarditis
- 4 events occurred within 10 days of receiving the vaccine, 1 event occurred within 2 weeks and 1 event occurred within 3 weeks following vaccination.
- 3 cases with comorbidities (HTN, dyslipidemia)
- All cases were discharged from the hospital and are under observation in the community
- 2 cases received a second dose with no adverse reactions reported

Myocarditis after second dose (N=56)

- 50 males and 6 females
- 37 cases of Myocarditis, 19 cases of Perimyocarditis
- 23 events occurred within 10 days of receiving the vaccine, 2 events occurred within 2 weeks, 1 events occurred within 3 weeks, 2 events occurred within 4 weeks following vaccination.
- 28 cases with comorbidities (HTN, smoking, asthma, dyslipidemia, DM, hypercholesterolemia)
- 53 cases were discharged from the hospital and are under observation at community level. 1 case is under investigation, 2 cases died (1 case fulminant myocarditis, 1 case is still under investigation)
- None of the cases reported adverse reactions after receipt of the first dose

Pericarditis following vaccination

To date, 15 cases of Pericarditis following vaccination have been reported

Pericarditis after first dose (N=5)

- 3 males, 2 females
- All events occurred within 4 days of receiving the vaccine.
- 2 cases with comorbidities (history of Pericarditis, heart valve)
- All cases were discharged from the hospital and are under observation in the community
- 3 cases received a second dose with no adverse reactions reported



Pericarditis after second dose (N=10)

- 6 males and 4 females
- 8 events occurred within 7 days of receiving the vaccine, 1 events occurred within 3 weeks, 1 events occurred within 5 weeks following vaccination.
- 8 cases with comorbidities (HTN, obesity, hypercholesterolemia, dyslipidemia, renal disease)
- 9 cases were discharged from the hospital and are under observation at community level. 1 is under investigation.
- None of the cases reported adverse reactions after receipt of the first dose





Myocarditis / Pericarditis following vaccination

Myocarditis / Perimyocarditis




Pericarditis






Hospitalizations reported following vaccination



Among 77 hospitalizations following receiving the first dose, 34 cases were related to neurological diseases out of which 30 cases had comorbidities, 25 hospitalizations were related to underlying cardiovascular diseases out of which 18 had comorbidities, 6 hospitalizations were related to allergic reactions, 2 infectious and 7 hospitalizations were related to other underlying diseases. 3 hospitalizations were related to pregnancy complications.



Among 95 hospitalizations following receiving the second dose, 75 cases were related to cardiovascular diseases and of those 38 were with significant underlying diseases. 10 hospitalizations were related to underlying neurological diseases and of those 8 were with significant underlying diseases and 4 hospitalizations were related to underlying respiratory diseases, and 8 hospitalizations were related to other underlying diseases.

Reports among vaccine recipients
 1st dose: 5,244,481 2nd dose: 4,785,534





Deaths reported following vaccination

- **48 persons were reported to die in proximity to vaccination (up to 30 days following vaccination).**
- **42 deaths occurred within 10 days following vaccination**
- **Out of 48 reported cases, 14 are <60 y old:**
 - **2 were diagnosed in ER with myocarditis (1 case fulminant myocarditis, 1 case still under investigation)**
 - **2 PM in cases of sudden death excluded myocarditis in one and showed blocked LAD.**
 - **10 cases are under investigation: relatively young persons with sudden death.**

Reports among vaccine recipients
1st dose: 5,244,481 2nd dose: 4,785,534



Deaths reported following vaccination



Reports among vaccine recipients
 1st dose: 5,244,481 2nd dose: 4,785,534



Deaths reported following vaccination observed and expected



Age group	Mortality cases reported following 1 st dose	Mortality cases expected all causes (Dec-Mar)	Sudden death reported following 1st dose	Sudden death expected (Dec-Mar)	Mortality cases reported following 2 nd dose	Mortality cases expected all causes (Jan-Mar)	Sudden death reported following 2 nd dose	Sudden death expected (Jan-Mar)	Total cases reported
Male									
20-29	0	74	0	0	0	48	0	0	0
30-39	0	108	0	0	1	72	1	0	1
40-49	0	235	0	1	4	165	4	1	4
50-59	2	564	2	5	3	392	2	4	5
60-69	4	1220	1	5	2	865	0	3	6
70-79	6	2353	0	6	1	1727	0	3	7
80<	3	4349	0	9	3	3153	0	6	6
Female									
20-29	0	30	0	0	1	20	0	0	1
30-39	0	59	0	0	0	41	0	0	0
40-49	1	139	1	0	0	95	0	0	1
50-59	1	336	1	1	1	235	1	1	2
60-69	3	773	0	1	0	561	0	1	3
70-79	2	1714	1	4	4	1252	0	3	6
80<	3	5398	0	13	3	3889	0	10	6
Total	25	17,352	6	45	23	12,515	8	32	48

Note: Despite normalization to the number of vaccinees, observed and expected rates cannot be directly compared, because the observed cases are counted differently than the expected ones. The observed cases count deaths within a time window of a defined event (vaccine administration). The expected cases are calculated by the cumulative incidence over several calendar months. However, the expected cases do give a general order of magnitude for comparison of deaths following vaccine administration.

No specific signal associated with all causes of death and specifically sudden death

The overall mean of expected total deaths in the population of Israel 2015-2018, for December-March for the first dose, and January-March for the second dose, normalized for the number of vaccinated persons.



R-2024-00044

A-00000749473

"UNCLASSIFIED"

11/21/2024



COVID-19 vaccination Israel "BACK TO LIFE"

Enclosure 5

From: Markowitz, Lauri (CDC/DDID/NCIRD/DVD)
Sent: Mon, 5 Apr 2021 16:08:26 +0000
To: Anderson, Steven (FDA/CBER); Beresnev, Tatiana (NIH) [C]; Broder, Karen (CDC/DDID/NCEZID/DHQP); Calvert, Geoffrey M. (CDC/NIOSH/WTCHP); Clark, Matthew (IHS/ALB); Clark, Thomas A. (CDC/DDID/NCIRD/DVD); Cohn, Amanda (CDC/DDID/NCIRD/OD); Collins, Limone; Daley, Matt; Destefano, Frank (CDC/DDID/NCEZID/DHQP); Dooling, Kathleen L. (CDC/DDID/NCIRD/DVD); Edwards, Kathy; Farizo, Karen (FDA/CBER); Forshee, Richard (FDA/CBER); Gee, Julianne (CDC/DDID/NCEZID/DHQP); Helfand, Rita (CDC/DDID/NCEZID/OD); Hiers, Susan G. (CDC/DDID/NCIRD/OD); Hopkins, Bob; Jackson, Lisa; Kelman, Jeffrey A. (CMS/CM); Kuldorf, Martin; LaPorte, Kathleen (CDC/DDID/NCIRD/ID); Lee, Grace; MacNeil, Jessica R. (CDC/DDID/NCIRD/OD); Markowitz, Lauri (CDC/DDID/NCIRD/DVD); Marquez, Paige L. (CDC/DDID/NCEZID/DHQP); Mbaeyi, Sarah (CDC/DDID/NCIRD/OD); Mullen, Jennifer (CDC/DDID/NCEZID/DHQP); Myers, Tanya R. (CDC/DDID/NCEZID/DHQP); Nair, Narayan (FDA/CBER); Oliver, Sara Elizabeth (CDC/DDID/NCIRD/DVD); Patricia Whitley-Williams (whitlepn@rwjms.rutgers.edu); Riley, Laura; Rubin, Mary (HRSA); Schechter, Robert; Shanley, Edwin (CDC/DDID/NCIRD/OD); Shay, David (CDC/DDID/NCIRD/ID); Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP); Sotir, Mark (CDC/DDID/NCIRD/DVD); Steinberg, Judith (HHS/OASH); Su, John (CDC/DDID/NCEZID/DHQP); Talbot, Keipp; Wasley, Annemarie (CDC/DDPHSIS/CGH/GID); Weintraub, Eric (CDC/DDID/NCEZID/DHQP); Wharton, Melinda (CDC/DDID/NCIRD/ISD); Wong, Hui-Lee (FDA/CBER); Woo, Jared (CDC/DDID/NCEZID/DHQP); Young, Mardia (CDC/DDID/NCEZID/DHQP) (CTR)
Subject: [EXTERNAL] VaST - Agenda for April 5 (1:30 - 3 pm ET) and presentations - CONFIDENTIAL
Attachments: (b)(5)
(b)(5)
2021_04_05 VaST Meeting Agenda.docx

Dear all,

This email includes the VaST agenda for today (below and attached) as well as 4 slide sets. The agenda attached has more information regarding approximate times for talks and discussion.

Agenda:

(b)(5); (b)(6)

The VaST call link information should be on your calendars.
Reminder - all VaST documents and communications are confidential.

Lauri Markowitz and Melinda Wharton

Lauri Markowitz, MD
VaST Co-Lead
Division of Viral Diseases
National Center for Immunization and Respiratory Diseases

United States Senate

COMMITTEE ON
HOMELAND SECURITY AND GOVERNMENTAL AFFAIRS
WASHINGTON, DC 20510-6250

DAVID M. WEINBERG, STAFF DIRECTOR
WILLIAM E. HENDERSON III, MINORITY STAFF DIRECTOR
LAURA W. KILBRIDE, CHIEF CLERK

December 13, 2024

The Honorable Xavier Becerra
Secretary
Department of Health and Human Services

Dear Secretary Becerra:

In February 2020, *Nature Microbiology* published a paper by Drs. Michael Letko and Vincent Munster, two researchers at the National Institutes of Health's research facility, Rocky Mountain Laboratories (RML), entitled "Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses."¹ According to that paper, Drs. Letko and Munster purchased DNA sequences from Integrated DNA Technologies, Inc. (IDT).² In October 2024, my office requested the Department of Health and Human Services (HHS) authorize IDT to release the order forms to my office relating to Drs. Letko and Munster's research. To date, HHS has failed to comply with my office's requests. As a result of HHS's failure to respond to my office's requests, I am now sending this formal letter and putting HHS on notice—if HHS does not fully comply with the following requests by December 30, 2024, I will plan to subpoena this information when I become chairman of the Permanent Subcommittee on Investigations. Please provide:

1. All order forms for DNA sequences from or sent on behalf of employees at Rocky Mountain Laboratories, including Drs. Michael Letko and Vincent Munster, to Integrated DNA Technologies, Inc. from January 1, 2019 to December 31, 2020.
2. All purchase receipts for orders of DNA sequences from or sent on behalf of employees at Rocky Mountain Laboratories, including Drs. Michael Letko and Vincent Munster, to Integrated DNA Technologies, Inc. from January 1, 2019 to December 31, 2020.

¹ Michael Letko, Andrea Marzi, and Vincent Munster, Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses, *Nature Microbiology*, Feb. 24, 2020, <https://www.nature.com/articles/s41564-020-0688-y>. The preprint was published on Jan. 22, 2020. See <https://www.biorxiv.org/content/10.1101/2020.01.22.915660v1.full.pdf>; @quay_dr, Dr. Steven Quay, X, Apr. 17, 2024, https://x.com/quay_dr/status/1780789005996666933.

² Michael Letko, Andrea Marzi, and Vincent Munster, Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses, *Nature Microbiology*, Feb. 24, 2020, <https://www.nature.com/articles/s41564-020-0688-y> at 568.

The Honorable Xavier Becerra
Dec. 13, 2024
Page 2

Thank you for your attention to this matter.

Sincerely,



Ron Johnson
Ranking Member
Permanent Subcommittee on Investigations

cc: The Honorable Richard Blumenthal
Chairman
Permanent Subcommittee on Investigations

The Honorable Christi Grimm
Inspector General
Department of Health and Human Services